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ABSTRACT
Objectives: To develop evidence-based guideline recommen-
dations through a systematic review of the literature to estab-
lish standard molecular biomarker testing of colorectal cancer
(CRC) tissues to guide epidermal growth factor receptor
(EGFR) therapies and conventional chemotherapy regimens.
Methods: The American Society for Clinical Pathology,
College of American Pathologists, Association for Molecular
Pathology, and American Society of Clinical Oncology con-
vened an expert panel to develop an evidence-based guideline
to establish standard molecular biomarker testing and guide
therapies for patients with CRC. A comprehensive literature
search that included more than 4,000 articles was conducted.
Results: Twenty-one guideline statements were established.
Conclusions: Evidence supports mutational testing for
EGFR signaling pathway genes, since they provide clinic-
ally actionable information as negative predictors of benefit
to anti-EGFR monoclonal antibody therapies for targeted
therapy of CRC. Mutations in several of the biomarkers
have clear prognostic value. Laboratory approaches to op-
erationalize CRC molecular testing are presented.
© 2017 American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology,
American Society of Clinical Oncology, and American Society for Investigative Pathology. All rights reserved.
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Molecular testing to select targeted and conventional
therapies for patients with colorectal cancer (CRC) has been
the focus of a number of recent studies and is becoming
standard practice for management of patients with CRC.
Molecular markers that predict response to a specific ther-
apy or treatment regimen are known as predictive bio-
markers.1 Monoclonal antibody therapies that target the
epidermal growth factor receptor (EGFR) bind the EGFR
extracellular domain, blocking EGFR signaling pathways.
Anti-EGFR monoclonal antibodies have been the main tar-
geted therapies for CRC that require knowledge of the muta-
tional status of genes in the pathway as predictive
biomarkers of response to these therapies.2-4 Initial clinical
trial data demonstrated that patients with CRC carrying acti-
vating mutations of KRAS affecting exon 2 codons 12 and
13 did not benefit from anti-EGFR monoclonal antibody
therapy.2-4 Subsequent studies described other mutations in
genes of the EGFR signaling pathways involving other
exons of KRAS and in NRAS, BRAF, PIK3CA, and PTEN
that may affect response of CRC to anti-EGFR antibody
therapies. Guidelines addressing the molecular testing of
EGFR pathway genes beyond KRAS have not been estab-
lished and are needed in clinical practice.
The DNA mismatch repair (MMR) status of CRC may
have predictive value in some clinical settings. While test-
ing of CRC for MMR has been recommended for all pa-
tients with CRC as a workup test to evaluate for possible
Lynch syndrome,5 guidelines for the use of MMR as a pre-
dictive biomarker of response to therapy have not been re-
ported. Recent molecular biomarker data have shown the
importance of microsatellite instability (MSI) testing, a
marker of deficient mismatch repair (dMMR), for the selec-
tion of patients for immunotherapy (see section on emerging
biomarkers below).
Alterations of a number of critical genes in CRC devel-
opment and progression such as dMMR and BRAF activat-
ing mutations have been shown to affect prognosis, as
measured by several metrics of tumor progression or sur-
vival.6-8 The utility of incorporating prognostic biomarkers
in the management of patients with CRC has not been well
defined in clinical practice. Defining the utility of informa-
tion gathered from prognostic molecular biomarkers for
clinical management of patients with CRC is warranted.
The postgenome era and the emphasis on precision
genomic-based medicine are providing enormous amounts
of new data and many promising new molecular cancer bio-
markers that may emerge as molecular diagnostic tools that
can be used to enhance successful treatment of patients with
CRC and other cancers. Laboratories and regulatory agen-
cies are faced with challenges to rapidly and efficiently pro-
vide new test results for the management of patients with
cancer. Laboratory testing of molecular biomarkers involves
the selection of assays, type of specimens to be tested, tim-
ing of ordering of tests, and turnaround time for testing re-
sults. Recent years have shown that a plethora of technical
approaches can effectively be used as long as test specificity
and sensitivity meet the clinical needs. While earlier testing
approaches were focused on one or a few testing targets, the
current need for multiple molecular markers from potentially
minute tumor samples is leading to greater use of gene panels
such as targeted next-generation sequencing (NGS) cancer
panels, which can assay from a few to hundreds of genes and
amplicons with known mutational hotspots in cancer.
There is a need for current evidence-based recommen-
dations for the molecular testing of CRC tissues to guide
EGFR-targeted therapies and conventional chemotherapy
regimens. Therefore, the current recommendations were de-
veloped through collaboration of four societies: American
Society for Clinical Pathology (ASCP), College of
American Pathologists (CAP), Association for Molecular
Pathology (AMP), and American Society of Clinical
Oncology (ASCO). This guideline follows well-established
methods used in their development as well as for regular up-
dates, such that new advances in the molecular testing for
clinical management of CRC can be integrated in future up-
dates of the guideline in a timely manner.
Panel Composition
The ASCP, the CAP Pathology and Laboratory Quality
Center (the Center), the AMP, and the ASCO convened an
expert panel consisting of practicing pathologists, oncolo-
gists, geneticists, and a biostatistician with expertise and
experience in molecular biomarker testing and targeted
therapies for CRC. The ASCP, CAP, AMP, and ASCO
jointly approved the appointment of the project, cochairs,
and expert panel members. In addition, a methodologist
experienced in systematic review and guideline develop-
ment consulted with the panel throughout the project.
Conflict of Interest Policy
Prior to acceptance on the expert or advisory panel,
potential members completed a joint guideline conflict of
interest (COI) disclosure process, whose policy and form (in
effect July 2011) require disclosure of material financial
interest in, or potential for benefit of significant value from,
the guideline’s development or its recommendations 12
months prior through the time of publication. The potential
members completed the COI disclosure form, listing any
relationship that could be interpreted as constituting an
actual, potential, or apparent conflict. All project partici-
pants were required to disclose conflicts prior to beginning
and continuously throughout the project’s timeline.
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Disclosed conflicts of the expert panel members are listed in
Appendix 1 and Appendix 2 .
The ASCP, CAP, AMP, and ASCO provided funding
for the administration of the project; no industry funds were
used in the development of the guideline. All panel mem-
bers volunteered their time and were not compensated for
their involvement, except for the contracted methodologist.
Please see the Supplemental Digital Content (SDC) at
American Journal of Clinical Pathology online for full
details on the COI policy.
Objective
The scope of the project was to develop an evidence-
based guideline to help establish standard molecular bio-
marker testing, guide targeted therapies, and advance
personalized care for patients with CRC. The panel addressed
the following key questions:
1. What biomarkers are useful to select patients with CRC
for targeted and conventional therapies?
2. How should tissue specimens be processed for bio-
marker testing for CRC management?
3. How should biomarker testing for CRC management be
performed?
4. How should molecular testing of CRC be implemented
and operationalized?
5. Are there emerging genes/biomarkers that should be
routinely tested in CRC?
Materials and Methods
This evidence-based guideline was developed follow-
ing standards as endorsed by the Institute of Medicine.9 A
detailed description of the methods and systematic review
(including the quality assessment and complete analysis of
the evidence) can be found in the SDC.
Literature Search and Selection
A comprehensive search for literature was performed in
MEDLINE using the OvidSP (August 1, 2013) and PubMed
(September 17, 2013) interfaces. The initial MEDLINE
search encompassed the publication dates of January 1, 2008,
through August 1, 2013 (OvidSP), and January 1, 2008,
through September 17, 2013 (PubMed). A supplemental lit-
erature search was performed using Scopus (September 25,
2013) to identify relevant articles published between
January 1, 2008, and September 25, 2013, in journals not
indexed in MEDLINE. The literature search of the elec-
tronic databases involved two separate searches in each
database, the first using Medical Subject Headings (MeSH)
terms and keywords for the concepts “colorectal cancer,”
“biomarkers,” “treatment,” and “treatment outcomes” and
the second using terms for the concepts “colorectal cancer,”
“biomarkers,” and “laboratory methods.” Limits were set
for human studies published in English, and a publication
filter was applied to exclude lower levels of evidence such
as letters, commentaries, editorials, and case reports. The
Ovid search was rerun on February 12, 2015, to identify
articles published since August 1, 2013.
In addition to the searches of electronic databases, an
Internet search of international health organizations, the
National Guidelines Clearinghouse, and Guidelines
International Network was conducted for existing relevant
guidelines or protocols. Guidelines were included if they
were published since 2008 in English. The proceedings of the
meetings of the ASCO and ASCO-Gastrointestinal Cancers
Symposium, European Society for Medical Oncology, and
the American Association for Cancer Research from 2012
and 2013 were also searched for relevant abstracts.
A focused examination of all systematic reviews
retrieved by the initial literature search and retained after
full-text review was performed to identify primary research
studies not already included. In addition, recommendations
from the expert panel were reviewed, and the reference lists
of all articles deemed eligible for inclusion were scanned
for relevant reports. The results of all searches were com-
bined and deduplicated.
Detailed information regarding the literature search
strategy can be found in the SDC.
Eligible Study Designs
Practice guidelines, consensus documents, systematic
reviews, meta-analyses, randomized controlled trials, com-
parative studies, reviews, and evaluation studies were eligi-
ble for inclusion. In addition to journal articles, the search
identified meeting abstracts.
Inclusion Criteria
Published studies were selected for full-text review if
they met each of the following criteria:
1. Patients with colorectal or rectal cancer with a pathol-
ogy diagnosis of adenocarcinoma or adenocarcinoma
with neuroendocrine differentiation, either primary or
metastatic
2. Patients of all ages
3. Patients with cancer of any invasive stage (T1-T4)
4. Biomarker testing such as KRAS (Kirsten rat sarcoma
viral oncogene homolog), DNA MMR/MSI, BRAF
(V-raf murine sarcoma viral oncogene homolog B1), NRAS
(neuroblastoma RAS viral [v-ras] oncogene homolog),
PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase,
catalytic subunit alpha), PTEN (phosphatase and tensin
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homolog), MLH1 (MutL homolog 1) methylation, or
gene expression profiles
5. Comparative studies
6. Human studies
7. Studies published in English
Exclusion Criteria
1. All other tumor primaries and types (ie, noncolorectal or
nonrectal cancers, tumor types other than adenocarci-
noma or adenocarcinoma with neuroendocrine
differentiation)
2. Patients with noninvasive tumors (ie, intraepithelial,
dysplasia, in situ, polyps without carcinoma)
3. Studies of colorectal cancers without biomarker testing,
novel biomarkers—for example, VEG-F (vascular endo-
thelial growth factor), XRCC1 (X-ray repair comple-
menting defective repair in Chinese hamster cells 1),
IGF (insulin-like growth factor), ERCC (excision repair
cross-complementing rodent repair deficiency, comple-
mentation group 1), micro-RNA, TYMS (thymidylate
synthetase), GCC (guanylyl cyclase C), LINE (long
interspersed nucleotide element) methylation, CIMP
(CpG island methylator phenotype), HER2 (V-erb-b2
erythroblastic leukemia viral oncogene homolog 2),
CIN (chromosomal instability) status LOH (loss of het-
erozygosity), and germline (genetics only) testing
4. Non-English-language articles
5. Animal studies
6. Studies published prior to 2002
7. Noncomparative studies, letters, commentaries, or
editorials
8. Studies that did not address at least one of the defined
inclusion criteria
9. Studies with fewer than 50 patients per comparison arm
Outcomes of Interest
The primary outcomes of interest included survival out-
comes and performance characteristics of laboratory testing
assays. Survival outcomes included overall survival (OS),
disease-free survival (DFS), progression-free survival
(PFS), recurrence-free survival, time to recurrence, response
to therapy (eg, complete and partial response). Laboratory
data and test performance characteristics included percent
mutation, concordance of testing methods, sensitivity of
testing methods, specificity of testing methods, concordance
of detected mutations between primary and metastatic muta-
tions (number [%] of cases with mutations vs number of
cases with no mutations in the gene of interest), and con-
cordance of mutations (synchronous primary vs metastatic,
metachronous primary vs metastatic, between synchronous
metastases, between metachronous metastases).
Quality Assessment
An assessment of the quality of the evidence was per-
formed for all retained studies following application of the
inclusion and exclusion criteria by the methodologist. Using
this method, studies deemed to be of low quality would not
be excluded from the systematic review but would be
retained and their methodologic strengths and weaknesses
discussed where relevant. Studies would be assessed by con-
firming the presence of items related to both internal and
external validity, which are all associated with method-
ologic rigor and a decrease in the risk of bias. The quality
assessment of the studies was performed by determining the
risk of bias by assessing key indicators, based on study
design, against known criteria. (Refer to the SDC for
detailed discussion of the quality assessment.)
For strength of the evidence, the panel considered the
level of evidence, as well as its quantity and quality of
included studies. The level of evidence was based on the
study design as described in Table 1 .10 In general, level I
and II evidence is considered most appropriate to answer
clinical questions, but in the absence of such high-quality
evidence, the panel considered data from lower quality stud-
ies. The quantity of evidence refers to the number of studies
and number of cases included for each outcome in the rec-
ommendation. The quality of studies reflects how well the
studies were designed to eliminate bias and threats to
validity.
The appropriateness of the study design and data col-
lected, relevance and clarity of findings, and adequacy of
conclusions were evaluated. Each study was assessed indi-
vidually (refer to the SDC for individual assessments and
results) and then summarized by study type. Components
such as generalizability and applicability were also consid-
ered when determining the strength of evidence. A summary
of the overall quality of the evidence was given considering
the evidence in totality. Ultimately, the designation (ie, rat-
ing or grade) of the strength of evidence is a judgment by
Table 1
Levels of Evidencea
Level Description
Level I Evidence derived from systematic reviews of appropriate
level II studies and/or clinical practice guidelines
Level II Evidence derived from randomized controlled trials
Level III Evidence derived from comparative studies (eg, prospec-
tive cohort studies, retrospective cohort studies)
Level IV Evidence without a comparator (eg, case reports, case
series, narrative reviews)
aData derived from National Health and Medical Research Council.10
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the expert panel of its level of confidence that the evidence
from the studies informing the recommendations reflects
true effect. Table 2 describes the grades for strength of
evidence.11
Assessing the Strength of Recommendations
Development of recommendations requires that the
panel review the identified evidence and make a series of
key judgments (using procedures described in the SDC).
Grades for strength of recommendations were developed by
the CAP Pathology and Laboratory Quality Center and are
described in Table 3 .11
Guideline Revision
This guideline will be reviewed every 4 years or earlier
in the event of publication of substantive and high-quality
evidence that could potentially alter the original guideline
recommendations. If necessary, the entire panel will recon-
vene to discuss potential changes. When appropriate, the
panel will recommend revision of the guideline to the
ASCP, CAP, AMP, and ASCO for review and approval.
Disclaimer
Practice guidelines and consensus statements reflect the
best available evidence and expert consensus supported in
practice. They are intended to assist physicians and patients
in clinical decision making and to identify questions and set-
tings for further research. With the rapid flow of scientific
information, new evidence may emerge between the time a
practice guideline or consensus statement is developed and
when it is published or read. Guidelines and statements are
not continually updated and may not reflect the most recent
Table 2
Grades for Strength of Evidencea
Designation Description Quality of Evidence
Convincing High confidence that available evidence reflects true
effect. Further research is very unlikely to change the
confidence in the estimate of effect.
High/intermediate quality of evidence
Adequate Moderate confidence that available evidence reflects true
effect. Further research is likely to have an important
impact on the confidence in estimate of effect and may
change the estimate.
Intermediate/low quality of evidence
Inadequate Little confidence that available evidence reflects true
effect. Further research is very likely to have an impor-
tant impact on the confidence in the estimate of effect
and is likely to change the estimate.
Low/insufficient quality of evidence and expert panel uses
formal consensus process to reach recommendation
Insufficient Evidence is insufficient to discern net effect. Any estimate
of effect is very uncertain.
Insufficient evidence and expert panel uses formal con-
sensus process to reach recommendation
aAdapted from Guyatt et al,11 by permission of BMJ Publishing Group Limited.
Table 3
Grades for Strength of Recommendationa
Designation Recommendation Rationale
Strong recommendation Recommend for or against a particular molecular
testing practice for colorectal cancer (can include
must or should)
Supported by convincing or adequate strength of evi-
dence, high or intermediate quality of evidence, and
clear benefit that outweighs any harms
Recommendation Recommend for or against a particular molecular
testing practice for colorectal cancer (can include
should ormay)
Some limitations in strength of evidence (adequate or
inadequate) and quality of evidence (intermediate or
low), balance of benefits and harms, values, or costs,
but panel concludes that there is sufficient evidence
and/or benefit to inform a recommendation
Expert consensus opinion Recommend for or against a particular molecular
testing practice for colorectal cancer (can include
should ormay)
Serious limitations in strength of evidence (inadequate of
insufficient), quality of evidence (intermediate or low),
balance of benefits and harms, values, or costs, but
panel consensus is that a statement is necessary
No recommendation No recommendation for or against a particular
molecular testing practice for colorectal cancer
Insufficient evidence or agreement of the balance of ben-
efits and harms, values, or costs to provide a
recommendation
aData derived from Guyatt et al.11
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evidence. Guidelines and statements address only the topics
specifically identified therein and are not applicable to other
interventions, diseases, or stages of diseases. Furthermore,
guidelines and consensus statements cannot account for
individual variation among patients and cannot be consid-
ered inclusive of all proper methods of care or exclusive of
other treatments. It is the responsibility of the treating physi-
cian or other health care provider, relying on independent
experience and knowledge, to determine the best course of
treatment for the patient. Accordingly, adherence to any
practice guideline or consensus statement is voluntary, with
the ultimate determination regarding its application to be
made by the physician in light of each patient’s individual
circumstances and preferences. The ASCP, CAP, AMP, and
ASCO make no warranty, express or implied, regarding
guidelines and statements and specifically exclude any war-
ranties of merchantability and fitness for a particular use or
purpose. The ASCP, CAP, AMP, and ASCO assume no
responsibility for any injury or damage to persons or prop-
erty arising out of or related to any use of this statement or
for any errors or omissions.
Results
A total of 4,197 studies met the search term require-
ments. A total of 123 articles were included for data extrac-
tion. Excluded articles were available as discussion or
background references. The panel convened 14 times (11
teleconference webinars and three face-to-face meetings)
from July 27, 2013, through September 24, 2015, to develop
the scope, draft recommendations, review and respond to
solicited feedback, and assess the quality of evidence that
supports the final recommendations. Additional work was
completed via electronic mail. An open comment period
was held from March 30, 2015, through April 22, 2015, dur-
ing which draft recommendations were posted on the AMP
website. Twenty-one guideline statements had an agreement
ranging from 60% to 94% for each statement from the open-
comment period participants (refer to Outcomes in the SDC
for full details). The website received a total of 248 com-
ments. Teams of three to four expert panel members were
assigned three to five draft recommendations to review all
comments received and provide an overall summary to the
rest of the panel. Following panel discussion and the final
quality of evidence assessment, the panel members deter-
mined whether to maintain the original draft recommenda-
tion as is, revise it with minor language change, or consider
it as a major recommendation change. The expert panel
modified eight draft statements based on the feedback dur-
ing the open-comment period and the considered judgment
process. Resolution of all changes was obtained by majority
consensus of the panel using nominal group technique
(rounds of email discussion and multiple edited recommen-
dations) among the panel members. The final recommenda-
tions were approved by the expert panel with a formal vote.
The panel considered the risks and benefits throughout the
whole process in their considered judgment process. Formal
cost analysis or cost-effectiveness was not performed.
Each organization instituted a review process to approve
the guideline. The ASCP assigned the review of the guideline
to a Special Review Panel. For the CAP, an independent
review panel (IRP) representing the Council on Scientific
Affairs was assembled to review and approve the guideline.
The IRP was masked to the expert panel and vetted through
the COI process. TheAMP approval process required the inter-
nal review of an independent panel led by the Publications and
Communications Committee Chair and Executive Committee
approval. The ASCO approval process required the review and
approval of the Clinical Practice Guidelines Committee.
Guideline Statements
1. Recommendation: Patients with CRC being consid-
ered for anti-EGFR therapy must receive RAS mutational test-
ing. Mutational analysis should include KRAS and NRAS
codons 12 and 13 of exon 2, 59 and 61 of exon 3, and 117 and
146 of exon 4 (“expanded” or “extended” RAS) Table 4 .
Aberrant activation of EGFR signaling pathways in
CRC is primarily associated with activating mutations of
genes in the mitogen-activated protein kinase and
phosphatidylinositol-3-kinase (PI3K) pathways. Together,
KRAS, NRAS, and BRAF mutations have been reported to
occur in more than half of all CRC cases, and KRAS or
NRAS and BRAF mutations are inversely associated, with a
small proportion of individual CRCs showing co-
occurrence of RAS and RAF mutations.3,12
Cetuximab and panitumumab are antibodies that bind
to the extracellular domain of EGFR, blocking the binding
of EGF and other EGFR endogenous ligands, thereby block-
ing EGFR signaling. Earlier studies reported the effects of
anti-EGFR antibody treatment independent of KRAS sta-
tus.13-16 However, it was later reported that targeted EGFR
therapies with cetuximab or panitumumab improve PFS and
OS in patients with metastatic CRC with wild-type KRAS
but not for patients with mutated KRAS.2,3,17 In these earlier
studies, only mutations of KRAS exon 2 were considered.
Based on the available clinical trial data in 2009, the ASCO
recommended that patients with metastatic CRC who are
candidates for anti-EGFR antibody therapy should have
their tumors tested for KRAS mutations in a Clinical
Laboratory Improvements Amendments ’88 (CLIA)–
accredited laboratory.2
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Table 4
Guideline Statements and Strength of Recommendations
Guideline Statement
Strength of
Recommendation
1. Patients with colorectal carcinoma being considered for anti-EGFR therapy must receive RASmutational
testing. Mutational analysis should include KRAS and NRAS codons 12 and 13 of exon 2, 59 and 61 of
exon 3, and 117 and 146 of exon 4 (“expanded” or “extended” RAS).
Recommendation
2a. BRAF p.V600 (BRAF c.1799 [p.V600]) mutational analysis should be performed in colorectal cancer tissue
in patients with colorectal carcinoma for prognostic stratification.
Recommendation
2b. BRAF p.V600 mutational analysis should be performed in deficient MMR tumors with loss of MLH1 to
evaluate for Lynch syndrome risk. Presence of a BRAFmutation strongly favors a sporadic pathogenesis.
The absence of a BRAFmutation does not exclude risk of Lynch syndrome.
3. Clinicians should order mismatch repair status testing in patients with colorectal cancers for the identifi-
cation of patients at high risk for Lynch syndrome and/or prognostic stratification.
Recommendation
4. There is insufficient evidence to recommend BRAF c.1799 p.V600 mutational status as a predictive
molecular biomarker for response to anti-EGFR inhibitors.
No recommendation
5. There is insufficient evidence to recommend PIK3CA mutational analysis of colorectal carcinoma tissue
for therapy selection outside of a clinical trial.
No recommendation
Note: Retrospective studies have suggested improved survival with postoperative aspirin use in patients
whose colorectal carcinoma harbors a PIK3CA mutation.
6. There is insufficient evidence to recommend PTEN analysis (expression by immunohistochemistry or
deletion by fluorescence in situ hybridization) in colorectal carcinoma tissue for patients who are being
considered for therapy selection outside of a clinical trial.
No recommendation
7. Metastatic or recurrent colorectal carcinoma tissues are the preferred specimens for treatment predictive
biomarker testing and should be used if such specimens are available and adequate. In their absence, pri-
mary tumor tissue is an acceptable alternative and should be used.
Expert consensus opinion
8. Formalin-fixed, paraffin-embedded tissue is an acceptable specimen for molecular biomarker mutational
testing in colorectal carcinoma. Use of other specimens (eg, cytology specimens) will require additional
adequate validation, as would any changes in tissue-processing protocols.
Expert consensus opinion
9. Laboratories must use validated colorectal carcinoma molecular biomarker testing methods with suffi-
cient performance characteristics for the intended clinical use. Colorectal carcinoma molecular biomarker
testing validation should follow accepted standards for clinical molecular diagnostics tests.
Strong recommendation
10. Performance of molecular biomarker testing for colorectal carcinoma must be validated in accordance
with best laboratory practices.
Strong recommendation
11. Laboratories must validate the performance of IHC testing for colorectal carcinoma molecular biomarkers
(currently IHC testing for MLH1, MSH2, MSH6, and PMS2) in accordance with best laboratory practices.
Strong recommendation
12. Laboratories must provide clinically appropriate turnaround times and optimal utilization of tissue speci-
mens by using appropriate techniques (eg, multiplexed assays) for clinically relevant molecular and immu-
nohistochemical biomarkers of colorectal cancer.
Expert consensus opinion
13. Molecular and IHC biomarker testing in colorectal carcinoma should be initiated in a timely fashion based
on the clinical scenario and in accordance with institutionally accepted practices.
Expert consensus opinion
Note: Test ordering can occur on a case-by-case basis or by policies established by the medical staff.
14. Laboratories should establish policies to ensure efficient allocation and utilization of tissue for molecular
testing, particularly in small specimens.
Expert consensus opinion
15. Members of the patient’s medical team, including pathologists, may initiate colorectal carcinoma molecu-
lar biomarker test orders in accordance with institutionally accepted practices.
Expert consensus opinion
16. Laboratories that require send-out of tests for treatment predictive biomarkers should process and send
colorectal carcinoma specimens to reference molecular laboratories in a timely manner.
Expert consensus opinion
Note: It is suggested that a benchmark of 90% of specimens should be sent out within 3 working days.
17. Pathologists must evaluate candidate specimens for biomarker testing to ensure specimen adequacy,
taking into account tissue quality, quantity, and malignant tumor cell fraction. Specimen adequacy find-
ings should be documented in the patient report.
Expert consensus opinion
18. Laboratories should use colorectal carcinoma molecular biomarker testing methods that are able to
detect mutations in specimens with at least 5%mutant allele frequency, taking into account the analytical
sensitivity of the assay (limit of detection or LOD) and tumor enrichment (eg, microdissection).
Expert consensus opinion
Note: It is recommended that the operational minimal neoplastic carcinoma cell content tested should be
set at least two times the assay’s LOD.
19. Colorectal carcinoma molecular biomarker results should be made available as promptly as feasible to
inform therapeutic decision making, both prognostic and predictive.
Expert consensus opinion
Note: It is suggested that a benchmark of 90% of reports be available within 10 working days from date
of receipt in the molecular diagnostics laboratory.
20. Colorectal carcinoma molecular biomarker testing reports should include a results and interpretation sec-
tion readily understandable by oncologists and pathologists. Appropriate Human Genome Variation
Society and Human Genome Organisation nomenclature must be used in conjunction with any historical
genetic designations.
Expert consensus opinion
(continued)
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A large body of evidence was available to guide the rec-
ommendation in the current guideline for RAS testing in col-
orectal cancers ( Table 5 and Supplemental Table 14; all
supplemental materials can be found at American Journal of
Clinical Pathology online). From 2008 to 2015, there were
311 primary studies that included 74,546 patients and
reported treatment outcomes for patients with RAS muta-
tions compared with nonmutated/wild type.12-16,18-45 The
most common comparison of anti-EGFR antibody treatment
outcomes was between KRAS mutation vs KRAS nonmu-
tated/wild type.18-20,22,24-26,28-31,33-42 Some studies also
compared the effects of adding an anti-EGFR inhibitor to
KRAS nonmutated/wild-type patients vs chemotherapy
alone.18,22,24,26,28,36-38 A few studies reported anti-EGFR anti-
body treatment outcomes for the following comparisons:
KRAS G13D vs codon 12 mutations,32 KRAS codon 13 muta-
tions vs other mutations,21 and G13D vs other exon 2
mutations.23
The reported anti-EGFR therapy outcomes in these
studies were pooled survival,13-16,21-27,29,32-37,39,41 pooled
PFS,13,15,16,18,21-27,29,31-36,39,41 and pooled objective
response rate (ORR).13,15,16,18,21,22,25,26,30-36,41 Thirteen
studies reported significant differences between compara-
tors.15,21,23-27,32,33,35-37,39 The systematic review literature
of data on anti-EGFR therapy outcomes is presented in
Supplemental Table 14. Five of these studies detected a sig-
nificant pooled survival advantage of anti–EGFR-treated
patients for KRAS nonmutated/wild type compared with
KRAS mutation.21,33,35,37,39 Three studies detected an
advantage for patients with nonmutated tumors given anti-
EGFR treatment compared with KRAS mutation-positive
patients given chemotherapy alone.24,26,36 Twenty of the
included studies pooled PFS,13,15,16,18,21-27,29,31-36,39,41 with
19 reporting significant differences between compara-
tors.13,15,18,21-27,29,31-36,39,41 Fourteen papers detected a signifi-
cant PFS advantage for adding an anti-EGFR inhibitor to
chemotherapy for KRAS nonmutated/wild-type patients com-
pared with chemotherapy alone.13,15,18,22,24-26,29,31,33,34,36,39,41
Sixteen of the included papers pooled ORR,13,15,16,18,21,22,25,26,30-36,41
with 14 reporting significant differences between compara-
tors.15,18,21,22,25,26,30-36,41 Eight studies detected ORR
advantages for adding an anti-EGFR inhibitor to
chemotherapy for patients with nonmutated/wild-type
tumors compared with chemotherapy
alone,18,25,26,30,33,34,36,41 and four detected an ORR advant-
age for KRAS nonmutated/wild-type patients over mutation
patients.22,31,32,35 Survival advantages (OS and PFS, ORR)
for G13D mutations over codon 12 and G13D over other
mutations were reported in two studies23,32 and codon 13
over other KRAS mutations.21
Recent studies showed conclusive evidence that in addi-
tion to mutations in KRAS exon 2, other RAS mutations in
KRAS exons 3 and 4 and NRAS exons 2, 3, and 4 were also
associated with nonresponse of metastatic CRC to anti-EGFR
monoclonal antibody therapy.12,44,46 Douillard et al44 pub-
lished a reanalysis of the Panitumumab Randomized Control
Trial in Combination with Chemotherapy for Metastatic
Colorectal Cancer to Determine Efficacy (PRIME) trial,
reporting that patients with any RAS mutations were associ-
ated with inferior PFS and OS with panitumumab-FOLFOX4
treatment, which was consistent with the findings previously
reported for patients with KRAS mutations in exon 2.
Subsequently, a meta-analysis of nine randomized clinical tri-
als provided further evidence that not all KRAS exon 2 non-
mutated/wild-type tumors benefit from anti-EGFR
monoclonal antibody treatment in metastatic CRC.12 Patients
with colorectal cancers that are KRAS exon 2 nonmutated/
wild type but harbor RAS mutations in KRAS exons 3 and 4
or NRAS exons 2, 3, and 4 also have significantly inferior
anti-EGFR treatment outcomes benefit compared with those
without any RAS mutations (Table 5 and Table 6 ). RAS
mutations occur mostly at exon 2, followed by mutations in
exons 3 and 4 Table 7 . The results suggest that “extended”
or “expanded” RAS mutation testing (KRAS exons 2, 3, and 4
and NRAS exons 2, 3, and 4) must be performed before the
administration of an anti-EGFR monoclonal antibody
therapy.12 In summary, current evidence indicates that both
cetuximab and panitumumab should only be prescribed for
patients with metastatic CRCs that are nonmutated/wild type
for all known RAS-activating mutations.12
This recommendation is supported by 34 studies,12-16,18-45,47
comprising 29 systematic studies,12,13,15,16,18-22,24-42,47 two
meta-analyses,14,23 one randomized controlled trial,44 one pro-
spective cohort study,45 and one retrospective cohort study.43
Table 4 (cont)
Guideline Statement
Strength of
Recommendation
21. Laboratories must incorporate colorectal carcinoma molecular biomarker testing methods into their over-
all laboratory quality improvement program, establishing appropriate quality improvement monitors as
needed to ensure consistent performance in all steps of the testing and reporting process. In particular,
laboratories performing colorectal carcinoma molecular biomarker testing must participate in formal profi-
ciency testing programs, if available, or an alternative proficiency assurance activity.
Strong recommendation
EGFR, epidermal growth factor receptor; IHC, immunohistochemistry; MMR, mismatch repair; PTEN, phosphatase and tensin homolog.
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Table 5
KRAS Clinical Practice Guidelines, Systematic Reviews, Meta-Analyses, Prospective Cohort Studies, and Retrospective Cohort
Studies
Author, Year
No. of Studies
(No. of Patients) Comparison Tests Used
Codons
Studied OS PFS ORR
CPGs, systematic reviews, and meta-analyses on KRASmutationþ vs mutation– (n¼30)
Petrelli et
al,35 2013
SR: 12 studies
including
2,226 patients
with mCRC
treated with
bevacizumab
Mutþ vs
Mut–
NR NR Median, HR,
0.65; 95% CI,
0.46-0.92;
P < .05, in
favor of Mut–
Median PFS,
HR, 0.85; 95%
CI, 0.74-0.98;
P < .05, in
favor of Mut–
KRASMutþ:
48.3% vs
KRASMut–:
54.8% (OR,
1.42; 95% CI,
1.05-1.92;
P < .05)
Mao et al,32
2013
SR: 10 studies
including
1,487 patients
with mCRC
treated with
cetuximab
p.G13D vs
codon 12
Mutþ
NR G13D, 12 HR, 0.52; 95%
CI, 0.33-0.80,
P < .05, in
favor of G13D
PFS, HR, 0.54;
95% CI, 0.36-
0.81, P < .05,
in favor of
G13D
KRAS pG13D:
22% KRAS 12:
16% KRAS
Mut–: 44%
(pG13D vs 12:
RR, 1.64; 95%
CI, 1.13-2.38;
P < .05)
pG13D vs
Mut–: RR, 0.54;
CI, 0.38-0.77;
P < .05)
Jiang et al,27
2013
SR: 13 studies
including
1,174 patients
with mCRC
treated with
cetuximab or
panitumumab
Increased vs
not
increased
EGRF GCN
FISH, CISH,
SISH, qPCR
NR Increased GCN
associated
with improved
OS among
patients
treated with
anti-EGFR
mAbs (HR,
0.62; 95% CI,
0.50-0.77;
P < .05)
GCN associated
with improved
PFS (HR, 0.65;
95% CI, 0.47-
0.89; P < .05)
NR
Hoyle et al,25
2013
SR-HTA: 2 stud-
ies including
EGFR-
expressing
mCRC
patients total
with cetuxi-
mab, bevaci-
zumab, or
panitumumab
in the second-
line and
greater
Mutþ vs
Mut–
NR NR Median, 9.5
months vs 4.8
months; HR,
0.55; 95% CI,
0.41-0.75,
P< .05, in favor
of cetuximab
over BSC in
Mut–
Panitumumab
þ BSC com-
pared with
BSC alone in
Mut–, P ¼ ns
Median PFS,
HR, 0.40; 95%
CI, 0.30-0.54,
P < .05, third-
line cetuximab
þ BSC com-
pared with
BSC alone in
Mut– Median
PFS, HR, 0.45;
95% CI, 0.34-
0.59, P < .05,
panitumumab
þ BSC com-
pared with
BSC alone in
Mut–
KRASMut–:
12.8% KRAS
Mutþ: 1.2%,
P < .05, cetux-
imab þ BSC
compared
with BSC
alone in Mut–
KRASMut–:
10% KRAS
Mutþ: 0, P <
.05, panitumu-
mab þ BSC
compared
with BSC
alone in Mut–
Chen et al,21
2013
SR: 7 studies
including
2,802 patients
with mCRC
Codon 13
Mutþ vs
other
mutations
PCR, direct
sequencing
13, other
Mutþ,
Mut–
Median OS: 14.6
months,
codon 13 11.8
months (other
mutation) 17.3
months, Mut–
Median PFS: 6.4
months,
codon 13 4.1
months (other
mutation) 6.6
months, Mut–
Codon 13 Mutþ
vs other muta-
tions: RR, 1.52
(95% CI, 1.10-
2.09, P < .05)
Codon 13
Mutþ vs Mut–
: RR, 0.61
(95% CI, 0.45-
0.83, P < .05)
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Table 5 (cont)
Author, Year
No. of Studies
(No. of Patients) Comparison Tests Used
Codons
Studied OS PFS ORR
Zhou et al,16
2012
SR: 4 RCTs
including
1,270 first-line
patients with
mCRC (all
Mut–)
Oxaliplatin
CT6 anti-
EGFR
mAbs
Anti-EGFR
þ CT vs CT
Mut– only HR, 1.00; 95%
CI, 0.88-1.13,
P ¼ ns
HR, 0.86; 95%
CI, 0.71-1.04,
P ¼ ns
RR, 1.08; 95%
CI, 0.86-1.36,
P ¼ ns
Zhang et al,41
2011
SR: 4 studies
including
2,912 patients
with mCRC
Mutþ vs
Mut–
NR NR Cetuximab þ CT
vs CT alone,
Mut–: HR,
0.84; 95% CI,
0.64-1.11, P ¼
ns Cetuximab
þ CT vs CT
alone, muta-
tion: HR, 1.03;
95% CI, 0.74-
1.44, P ¼ ns
Cetuximab þ CT
vs CT alone,
Mut–: HR,
0.64; 95% CI,
0.50-0.84, P <
.05, favors
þcetuximab
Cetuximab þ
CT vs CT
alone, muta-
tion: HR, 1.37;
95% CI, 0.81-
2.31, P ¼ ns
Cetuximab þ CT
vs CT alone:
RR, 1.93; 95%
CI, 1.14-3.26,
P < .05, favors
þcetuximab
CetuximabþC-
T vs CT alone,
Mut–: RR,
1.44; 95% CI,
1.20-1.73, P <
.05, favors
þcetuximab
Yang et al,40
2012
SR: 19 studies
including
1,077 patients
with mCRC
Mutþ vs
Mut–
GCNþ vs
GCN–
FISH,
qPCR,CISH
Exon 20 No pooling due
to statistical
heterogeneity
No pooling due
to statistical
heterogeneity
No pooling due
to statistical
heterogeneity
Vale et al,39
2012
SR: 10 RCTs
including
5,996 patients
with advanced
CRC
Mutþ vs
Mut–
NR NR NR Third line,
HR, 0.76; 95%
CI, 0.62-0.92,
P < .05
First/second line,
PFS, HR, 0.83;
95% CI, 0.76-
0.90, P < .05
Third line,
PFS, HR, 0.43;
95% CI, 0.35-
0.52, P < .05,
in favor of anti-
EGFR mAbs
for Mut– only
NR
Tsoukalas
et al,38
2012
SR: 13 studies
including
1,394 patients
with CRC
Mutþ vs
Mut–
Response
to cetuxi-
mab vs no
response
NR NR NR NR NR
Ross et al,42
2012
SR: Six studies
including
2,526 patients
with mCRC
Mutþ vs
Mut–
Antibody
vs control
Sanger, pyro-
sequenc-
ing, PCR,
ARMS,
Scorpion
NR NR NR NR
Ren et al,37
2012
SR: 23 studies
including
1,362 patients
with muta-
tions (100%
at codons 12
and 13, n¼1
at codon 61)
Mutþ vs
Mut–
—a 12, 13, 61 HR, 1.61; 95%
CI, 1.19-2.18,
P < .05, in
favor of treat-
ment in Mut–
vs Mutþ
patients
NR NR
Petrelli
et al,34
2012
SR: 4 RCTs
including 484
Mut– patients
with mCRC
Mutþ vs
Mut–
Cetuximab
and/or pan-
itumumab
þ CT vs CT
alone
NR NR P ¼ ns PFS, HR, 0.68,
P < .05, in
favor of adding
cetuximab
and/or panitu-
mumab to CT
in Mut–
patients
RR, 1.67,
P < .05, in
favor of adding
cetuximab
and/or panitu-
mumab to CT
in Mut–
patients
(continued)
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Table 5 (cont)
Author, Year
No. of Studies
(No. of Patients) Comparison Tests Used
Codons
Studied OS PFS ORR
Modest
et al,14
2012
M-A: 3 trials
including 119
patients with
mCRC with
codon 12
mutations vs
other
mutations
Cetuximab6
CT
NR 12 P ¼ ns NR NR
Loupakis
et al,31
2012
SR: 8 trials
including
6,609 patients
with mCRC
Mutþ vs
Mut–
NR NR NR PFS, HR, 0.91;
95% CI, 0.84-
0.99; P < .05,
in favor of add-
ing anti-EGFR
mAbs to CT in
Mut– patients
(irinotecan
favoring CT,
P < .05)
RR, 1.17; 95%
CI, 1.04-1.33;
P < .05, in
favor of KRAS
Mut–
Ku et al,28
2012
SR: 2 RCTs
including 261
patients with
mCRC
Cetuximab þ
5FU with
oxaliplatin
vs irinote-
can Mutþ
vs Mut–
NR NR No pooling per-
formed in this
comparison
AIO trial, P ¼
ns CECOG
trial, P < .05 in
favor of cetuxi-
mab þ
FOLFOX in
Mut– patients
No pooling per-
formed in this
comparison
AIO trial, P ¼
ns CECOG
trial, P ¼ ns in
favor of cetuxi-
mab þ
FOLFOX in
Mut– patients
NR
Petrelli
et al,15
2011
SR: 7 trials
including
5,212 patients
with advanced
CRC, KRAS
Mut– only
Cetuximab or
panitumu-
mab þ CT
vs BSC
NR NR HR, 0.84; 95%
CI, 0.73-0.98,
P < .05, in
favor of anti-
EGFR mAbs
vs no mAbs
in Mut–
patients
PFS, HR, 0.65;
95% CI 0.51-
0.83, P < .05,
in favor of anti-
EGFR mAbs
vs no mAbs
in Mut–
patients
RR, 1.69; 95%
CI, 1.20-2.38;
P < .05, in
favor of anti-
EGFR
Mao et al,33
2012
SR: 13 studies
including 576
patients with
mCRC, all
KRASMut–
treated with
anti-EGFR
mAbs
Mutþ vs
Mut–
Direct
sequenc-
ing, survey
analysis,
alleic dis-
crimination,
Sanger
PIK3CA
exon 9,
20
HR, 3.29; 95%
CI, 1.60-6.74;
P < .05
PFS, HR, 2.52;
95% CI, 1.33-
4.78, P < .05,
PIK3CA exon
20 mutations
associated
with signifi-
cantly shorter
PFS duration
RR, 0.25; 95%
CI, 0.05-1.19;
P < .05,
PIK3CA exon
20 mutations
associated
with lower
ORR
Lin et al,29
2011
SR: 8 studies
including
5,325 patients
with advanced
CRC
Mutþ vs
Mut–
NR NR P ¼ ns PFS, HR, 0.66;
95% CI, 0.53-
0.82, P < .05,
in favor of add-
ing anti-EGFR
to CT in Mut–
patients
NR
Ibrahim
et al,13
2011
SR: 4 studies
including
2,115 patients
with mCRC
with Mut–
KRAS
Panitumuma-
b-based
treatment
vs control
NR NR P ¼ ns PFS, HR, 0.58;
95% CI, 0.36-
0.93; P < .05,
in favor of add-
ing panitumu-
mab to CT in
Mut– patients
OR, 1.08; 95%
CI, 0.75-1.58;
P ¼ ns
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Table 5 (cont)
Author, Year
No. of Studies
(No. of Patients) Comparison Tests Used
Codons
Studied OS PFS ORR
Dahabreh
et al,22
2011
SR: 29 poolable
studies includ-
ing 5,032
patients with
mCRC treated
with anti-
EGFR mAbs
Mutþ vs Mut–
Mutþ vs
Mut–
Cetuximab
or panitu-
mumab þ
CT vs CT
alone
NR NR HR, 1.30; 95%
CI, 0.95-1.78,
P ¼ ns in
Mut– patients
PFS, HR, 2.22;
95% CI, 1.74-
2.84, P < .05,
in favor of anti-
EGFR þ CT in
Mut– patients
only
Positive likeli-
hood ratio,
7.35 (95% CI,
3.72-14.50)
Negative likeli-
hood ratio,
0.55 (95% CI,
0.49-0.61)
KRASmuta-
tions associ-
ated with
higher likeli-
hood of
response
failure
Baas et al,20
2011
SR: 21 studies
including
1,213
patients with
mCRC (one
study, N ¼
NR)
Concordance
between
KRAS
Mutþ/Mut–
between
primary and
metastases
Sequencing,
pyrose-
quencing,
PCR-RFLP,
SSCP, AS-
PCR, ASO
KRAS,
PIK3CA,
BRAF,
or of
loss of
PTEN
NR NR NR
Adelstein
et al,18
2011
SR: 11 studies
including
8,924 patients
with mCRC
treated with
anti-EGFR
mAbs
Mutþ vs
Mut–
Cetuximab
or panitu-
mumab þ
CT vs CT
alone
NR 12, 13, 61 NR PFS, HR, 0.80;
95% CI, 0.64-
0.99, P < .05,
in favor of anti-
EGFR mAbs
in Mut–
patients
RD, 15%; 95%
CI, 8%-22%, P
< .05, in favor
of KRASMut–
þ anti-EGFR
treatment
Qiu et al,36
2010
SR: 22 studies
including
2,188 patients
with mCRC
Mutþ vs
Mut–
Cetuximab
þ CT vs CT
alone
DS, surveyor
analysis,
qPCR, AD,
melting
curve
analysis
Exon 1, 2 Median OS, 6.9
vs 13.5
months, HR,
2.17; 95% CI,
1.72-2.74, P <
.05, longer
median sur-
vival shown in
Mut– patients
who received
anti-EGFR
mAbs þ CT
Median PFS, 3.0
vs 5.8 months,
HR, 1.94; 95%
CI, 1.62-2.33;
P < .05, lon-
ger median
PFS shown in
Mut– patients
who received
anti-EGFR
mAbs þ CT
KRASMut–:
39% KRAS
Mutþ: 14%
RR, 0.24; 95%
CI, 0.16-0.38,
P < .05
Health
Quality
Ontario,24
2010
SR: 14 observa-
tional studies
in patients
with advanced
CRC
Mutþ vs
Mut–
Cetuximab
or panitu-
mumab þ
CT vs CT
alone
NR NR Mean OS, MD,
4.11; 95% CI,
–5.60 to2.62,
P < .05, lon-
ger survival
detected in
Mut– patients
treated with
cetuximab
þirinotecan
Mean PFS, MD,
¼ –3.32; 95%
CI, –4.86 to
1.78, P< .05,
longer dura-
tion detected
in Mut–
patients
treated with
cetuximab þ
irinotecan
NR
Ibrahim
et al,26
2010
SR: 10 studies
including
2,703 patients
with mCRC
Mutþ vs
Mut–
Cetuximab
þ CT vs CT
alone
NR NR P < .05, in favor
of treatment
with cetuxi-
mab þ CT in
Mut– patients
PFS, P < .05, in
favor of treat-
ment with
cetuximab þ
CT in Mut–
patients
OR, 2.10; 95%
CI, 1.42-3.10,
P < .05
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Table 5 (cont)
Author, Year
No. of Studies
(No. of Patients) Comparison Tests Used
Codons
Studied OS PFS ORR
De Roock
et al,23
2010
MA: 7 studies
including 774
patients with
mCRC who
received
cetuximab-
based treat-
ment6 CT
pG13D vs
other
mutation
NR pG13D, 13 Median (95% CI):
pG13D: 7.6
months (5.7-
20.5) Other
mutations: 5.7
months (4.9-
6.8) Mut–: 10.1
months (9.4-
11.3) P< .05,
pG13D supe-
rior to other
mutations
Median (95% CI)
PFS: pG13D:
4.0 months
(1.9-6.2) Other
mutations: 1.9
months (1.8-
2.8) Mut–: 4.2
months (3.9-
5.4) P < .05,
pG13D supe-
rior to other
mutations
NR
Allegra
et al,19
2009
SR: 5 RCTs
including 627
patients with
mCRC and 5
single-arm
studies includ-
ing 247
patients
Mutþ vs
Mut–
PCR, direct
sequencing
12, 13 No pooling was
performed
No pooling was
performed
No pooling was
performed
Linardou
et al,30
2008
SR: 8 studies
including 817
patients with
mCRC (306
with KRAS
mutations)
Mutþ vs
Mut–
NR 12, 13, 61 NR NR
Sorich et al,12
2015
SR: 9 RCTs
including
5,948 patients
with mCRC
Mutþ vs
Mut– Anti-
EGFR mAb
treatment
effect size
between
RAS sub-
groups,
including
Mutþ vs
Mut–
Bidirectional
Sanger
sequenc-
ing, pyrose-
quencing,
MALDI-
TOF analy-
sis, and
WAVE-
based
Surveyor
analysis
KRAS/
NRAS
12, 13,
59, 61,
117,
146
RASMut– vs
RASMutþ:
HR, 0.72 (95%
CI, 0.56-0.92;
P < .01) RAS
Mut– superior
KRAS exon 2
mutant vs
new RAS
mutant: P ¼
ns RASMut–,
anti-EGFR vs
no anti-EGFR:
HR, 0.87 (95%
CI, 0.77-0.99;
P < .04) KRAS
exon 2 Mut–,
anti-EGFR vs
no anti-EGFR:
HR, 0.90 (95%
CI, 0.83-0.98;
P ¼ ns) Any
RASmutant,
anti-EGFR vs
no anti-EGFR:
HR, 1.08 (95%
CI, 0.97-1.21;
P ¼ ns) KRAS
exon 2
mutant, anti-
EGFR vs no
anti-EGFR:
HR, 1.05 (95%
CI, 0.95-1.17;
P ¼ ns)
RASMut– vs
RASMutþ:
HR, 0.60 (95%
CI, 0.48-0.76;
P< .001) RAS
Mut– superior
KRAS exon 2
mutant vs new
RASmutant:
P¼ ns RAS
Mut–, anti-
EGFR vs no
anti-EGFR: HR,
0.62 (95% CI,
0.50-0.76;
P< .001) KRAS
exon 2 Mut–,
anti-EGFR vs
no anti-EGFR:
HR, 0.68 (95%
CI, 0.58-0.80;
P < .001) Any
RASmutant,
anti-EGFR vs
no anti-EGFR:
HR, 1.12 (95%
CI, 0.94-1.34;
P ¼ ns) KRAS
exon 2
mutant, anti-
EGFR vs no
anti-EGFR:
HR, 1.14 (95%
CI, 0.95-1.36;
P ¼ ns)
NR
(continued)
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Of the 29 systematic reviews,12,13,15,16,18-22,24-42,47 only
three reported using a multidisciplinary panel,19,25,30 and
only one reported taking patient preferences into account,37
although 13 examined important patient sub-
types.12,15,16,18,21,22,24,27,30,33,37,39,40 All but one had well-
described and reported methods sections.42 Seven did not
report on conflict of interest.13,15,16,34,38,41,42 Only nine
rated the quality of the included evidence, and these same
nine were the only ones that reported on the strength of the
included evidence.16,18,21,22,24,25,32,37,39 None of the studies
included a plan for updating. None of the systematic reviews
reported industry funding, two reported no funding,16,31
and 11 did not report on the source of funding, if
any.13,15,26,32,34-36,38,41,42,47 Two of these systematic
reviews were deemed to have a low risk of bias,24,37 14
were deemed to have a low to moderate risk of
bias,12,16,18,19,21,22,25,27,29,30,32,35,39,47 12 were deemed to
have a moderate risk of bias,13,15,20,26,28,31,33,34,36,38,40,41
and one was deemed to have a high risk of bias.42
Of the two meta-analyses obtained,14,23 both had well-
reported and reproducible methods sections, both described
the planned pooling a priori, and both discussed the limita-
tions of their analyses. Neither was based on a systematic
review of the literature, and neither did a quality assessment
of the included studies. One reported nonindustry funding,23
and the other reported industry funding.14 One was deemed
to have a low to moderate risk of bias,23 and the other was
deemed to have a moderate risk of bias.14
The single randomized controlled trial did not report on
any details of the randomization, including blinding, the
Table 5 (cont)
Author, Year
No. of Studies
(No. of Patients) Comparison Tests Used
Codons
Studied OS PFS ORR
Randomized controlled trials (n¼1)
Douillard
et al,44
2013
RCT: reanalysis
of PRIME trial
(NCT:
00364013)
data, including
1,060 patients
RASMut6
and
FOLFOX4
6 anti-
EGFR mAb
PCR, Sanger,
Surveyor
KRAS/NRAS
12, 13,
61, 117,
146
Mut6 and anti-
EGFR
mAb6: 26
months vs
20.2 months
HR, 0.78 (95%
CI, 0.62-0.99;
P < .05) in
favor of Mut–
and þ anti-
EGFR mAb
Mut6 and anti-
EGFR
mAb6: 10.1
months vs 7.9
months HR,
0.72 (95% CI,
0.58-0.90;
P < .05) in
favor of Mut–
and þ anti-
EGFR mAb
NR
Prospective cohort studies (n¼1)
Etienne-
Grimaldi
et al,45
2014
251 patients KRASMutþ
vs KRAS
Mut–
NR KRAS 12,
13
NR RR, 2.40 (95%
CI, 1.27-4.55;
P < .05), RFS
shorter in
KRASMutþ
patients with
stage III
tumors
NR
Retrospective cohort studies (n¼1)
Bando
et al,43
2013
82 samples from
376 patients
All Mut– vs
KRAS 12,
13 vs
KRAS 61,
146
Luminex
xMAP vs
DS (con-
cordance
rate 100%)
KRAS 12,
13, 61,
146
All Mut–: 13.8
months (9.2-
18.4) vs KRAS
Mutþ: 8.2
months (5.7-
10.7; P < .05)
All Mut–: 6.1
months (3.1-
9.2) vs KRAS
Mutþ: 2.7
months (1.2-
4.2; P < .05)
All Mut–: 38.8%
vs KRAS
Mutþ: 4.8%,
P < .05
AD, allelic discrimination; AIO, German AIO colorectal study group; ARMS, amplification refractory mutation system; AS-PCR, allele-specific polymerase chain reaction;
ASO, allele-specific oligonucleotide; BRAF, proto-oncogene B-Raf/v-Raf murine sarcoma viral oncogene homolog B; BSC, best supportive care; CECOG, Central European
Cooperative Oncology Group; CI, confidence interval; CISH, chromogenic in situ hybridization; CPG, clinical practice guideline; CRC, colorectal cancer; CT, chemotherapy;
DS, direct sequencing; EGFR, epidermal growth factor receptor; FOLFOX4, folacin, 4-fluorouracil, oxaliplatin; FISH, fluorescence in situ hybridization; FOLFOX, folinic acid
(leucovorin calcium), 5-fluorouracil, and oxaliplatin; 5FU, fluorouracil; GCN, gene copy number; HR, hazard ratio; HTA, health technology assessment; KRAS, Kirsten rat sar-
coma viral oncogene homolog; M-A, meta-analysis; mAbs, monoclonal antibodies; MALDI-TOF, matrix-assisted laser desorption/ionization-time of flight; mCRC, metastatic
colorectal cancer; MD, mean difference; Mut–, mutation negative or wild type; Mutþ, mutation positive; NR, not reported; NRAS, neuroblastoma RAS viral (v-ras) oncogene
homolog; ns, nonsignificant; OR, odds ratio; ORR, objective response rate; OS, overall survival; PCR, polymerase chain reaction; PCR-RFLP, polymerase chain reaction–restric-
tion fragment length polymorphism; PFS, progression-free survival; PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha; PRIME, Panitumumab
Randomized Control Trial in Combination with Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy; PTEN, phosphatase and tensin homolog; qPCR, quantita-
tive polymerase chain reaction; RCT, randomized controlled trial; RAS, rat sarcoma viral oncogene homolog; RD, risk difference; RFS, recurrence-free survival; RR, response
rate; SISH, silver in situ hybridization; SR, systematic review; SSCP, single-strand conformation polymorphism; xMAP, multiplex assay.
aTests used by Ren et al37: hybridization, PCR, direct sequencing, topographic genotyping, AS-PCR, tissue transglutaminase enzyme, high-performance liquid chromatography,
pyrosequencing, capillary sequencing.
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expected effect size and power calculation, and the length
of follow-up.44 It did report on differences in baseline
patient characteristics. This trial did report at least partial
industry funding and was deemed to have a low to moderate
risk of bias.44
The single prospective cohort study reported a bal-
ance between treatment and assessment groups, reported
on baseline characteristics, and made adjustments in the
analysis when differences were found.45 It reported non-
industry funding and was deemed to have a low risk of
bias.45
The single retrospective cohort study reported that the
treatment and assessment groups were in balance and also
reported on baseline patient characteristics.43 It did not
report that adjustments were made in the analysis to account
for differences, where differences were found. This study
reported nonindustry funding and was deemed to have a low
risk of bias.43
All of the evidence that supported this recommendation
was assessed, and none was found to have methodologic
flaws that would raise concerns about their findings.
2a. Recommendation: BRAF p.V600 (BRAF c.1799
[p.V600]) position mutational analysis should be performed
in CRC tissue in selected patients with colorectal carcinoma
for prognostic stratification.
BRAF activating mutations occur in about 8% of
advanced disease patients with CRC47,48 and in approxi-
mately 14% of patients with localized stage II and III
CRC.8,49 As such, mutations in BRAF constitute a substan-
tial subset of patients with CRC. The key questions related
to BRAF mutations are whether patients whose cancers
Table 6
Outcomes of RASMutations and Anti-EGFR Therapy12
Overall Survival Progression-Free Survival
Characteristic HR (95% CI) P Value HR (95% CI) P Value
RAS nm vs RASmutation, RAS nm superior 0.72 (0.56-0.92) <.01 0.60 (0.48-0.76) <.001
KRAS exon 2 mutant vs new RASmutant ns ns
KRAS nm exon 2, anti-EGFR vs no anti-EGFR 0.90 (0.83-0.98) ns 0.68 (0.58-0.80) <.001
KRAS exon 2 mutant, anti-EGFR vs no anti-EGFR 1.05 (0.95-1.17) ns 1.14 (0.95-1.36) ns
RAS nm, anti-EGFR vs no anti-EGFR 0.87 (0.77-0.99) <.04 0.62 (0.50-0.76) <.001
Any RASmutant, anti-EGFR vs no anti-EGFR 1.08 (0.97-1.21) ns 1.12 (0.94-1.34) ns
CI, confidence interval; EGFR, epidermal growth factor receptor; HR, hazard ratio; KRAS, Kirsten rat sarcoma viral oncogene homolog; nm, nonmutated; ns, nonsignificant;
RAS, rat sarcoma viral oncogene homolog.
Table 7
Prevalence of New RASMutations Across Studiesa
Study New RAS Total,b % KRAS Exon 3,b % KRAS Exon 4,b % NRAS Exon 2,b% NRAS Exon 3,b% NRAS Exon 4,b%
Codons 59, 61 Codons 117, 146 Codons 12, 13 Codons 59, 61 Codons 117, 146
OPUS 26.3 5.9 9.3 6.8 5.1 0.8
PICCOLO 9.8 NRc 3.7d 6.3e NRc NE
20020408 17.6 4.8c 5.0 4.2 3.0c 1.1
20050181 20.5 4.6 7.9 2.3 5.8 0.0
PRIME 17.4 3.7c 5.6 3.4 4.1c 0.0
FIRE-3 16.0 4.3c 4.9d 3.8 2.0c 0.0
PEAK 20.1 4.1 7.7 5.4 5.9 0.0
COIN 8.4 2.1c NE 0.9f 3.0c NE
CRYSTAL 14.7 3.3 5.6 3.5 2.8 0.9
Summary (95% CI)g 19.9 (16.7-23.4) 4.3 (3.3-5.5) 6.7 (5.7-7.9) 3.8 (3.0-4.8) 4.8 (3.4-6.8) 0.5 (0.2-1.2)
CI, confidence interval; COIN, Combination Chemotherapy With or Without Cetuximab as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer Trial;
CRYSTAL, Cetuximab Combined with Irinotecan in First-Line Therapy for Metastatic Colorectal Cancer Trial; FIRE-3, FIRE-3, Folinic Acid and Irinotecan (FOLFIRI) Plus
Cetuximab vs FOLFIRI Plus Bevacizumab in First-Line Treatment Colorectal Cancer (CRC) Trial; NA, not applicable; NE, not evaluated; NR, evaluated but not reported;
OPUS, Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (BY217/M2-111) Trial; PEAK, Panitumumab Plus mFOLFOX6 vs
Bevacizumab Plus mFOLFOX6 for First-Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors Trial;
PICCOLO, Panitumumab and Irinotecan vs Irinotecan Alone for Patients With KRAS Wild-Type, Fluorouracil-Resistant Advanced Colorectal Cancer Trial; PRIME,
Panitumumab Randomized Trial in Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy Trial.
aModified from Sorich et al12 by permission of Oxford University Press on behalf of the European Society for Medical Oncology.
bNew RAS mutations are reported as a proportion of the KRAS exon 2 nonmutated/wild-type group.
cKRAS and NRAS codon 59 mutation was not evaluated.
dKRAS codon 117 mutation was not evaluated.
eExon 3 codon 61 mutations in addition to the exon 2 mutations.
fOnly NRAS mutation G12C evaluated.
gRandom-effects meta-analysis summary estimates.
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Table 8
BRAF Clinical Practice Guidelines, Systematic Reviews, Meta-Analyses, Prospective Cohort Studies, and Retrospective Cohort
Studies
Author,
Year
Study Type
and Evidence Comparison Tests Used
Codons
Studied OS PFS ORR
CPGs, systematic reviews, and meta-analyses (n¼8)
Parsons
et al,52
2012
SR: 36 studies
including
4,562 CRC
tumors
(BRAF), 43
studies
including
2,975 CRC
tumors
(MLH1)
Correlation
study
NR BRAF
p.V600E,
MLH1
NR NR NR
Mao
et al,51
2011
SR: 11 studies
including
1,046
patients
with mCRC
Mutþ vs
Mut–
NR V600E NR NR BRAFMutþ: 0
BRAFMut–:
36.3%; P < .05;
RR, 0.14; 95% CI,
0.04-0.53
Lin et al,50
2011
SR: 1 study of
649 patients
with mCRC,
all KRAS
Mut–; 6.5%
were BRAF
Mutþ
Mutþ vs
Mut–
NR V600E Shorter duration
in BRAFMutþ
patients, dif-
ference 28
weeks,
P < .05
PFS, shorter
duration in
BRAFMutþ
patients, dif-
ference 18
weeks,
P < .05
NR
Baas
et al,20
2011
SR: 7 studies
including
538 patients
with mCRC
Mutþ vs
Mut–
Sequencing,
pyrosequencing
V600E NR NR NR
Cui et al,53
2014
SR: 4 studies
including
1,245
patients
Mutþ vs
Mut– CT6
anti-EGFR
mAbs
PCR V600E NR NR Mutþ vs Mut– (all
KRASMut–): RR,
0.43 (95% CI,
0.16-0.75; P <
.05) in favor of
Mut– Mut6 vs
CT6 anti-EGFR
mAbs (all KRAS
Mut–): RR, 0.38
(95% CI, 0.20-
0.73; P < .05) in
favor of Mut–
Mutþ and CT6
anti-EGFR
mAbs; P ¼ ns
Mut– and KRAS
Mut– and CT6
anti-EGFR
mAbs: RR, 1.48
(95% CI, 1.28-
1.71; P < .05) in
favor of BRAF
Mut– with CTþ
anti-EGFR mAbs
Yang
et al,71
2013
SR: 17 studies
(patients, n
¼ NR)
Mutþ vs
Mut–
—a V600E, 599,
466, 469
(7 studies) BRAF
Mut6: HR,
2.74 (95% CI,
1.79-4.19; P <
.05) in favor of
BRAFMut–
(8 studies) BRAF
Mut6: HR,
2.59 (1.67,
4.03; P < .05)
in favor of
BRAFMut–
BRAFMut–: 46.4%
BRAFMut: 18.5%
P < .05 in favor of
BRAFMut–
(continued)
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carry a BRAF mutation have a poorer outcome compared
with BRAF mutation-negative tumors and whether the pres-
ence of a mutation predicts benefit from or lack thereof to
anti-EGFR therapy.
Four systematic reviews20,50-52 and three systematic
reviews that included meta-analyses47,48,53 pertaining to the
prognostic and predictive value of BRAF mutations in
patients with CRC were identified through our systematic
review process ( Table 8 and Supplemental Table 14). These
studies revealed that patients with advanced CRC who pos-
sess a BRAF mutation have significantly poorer outcomes as
measured by PFS and OS and have a decreased response rate
to anti-EGFR therapy relative to those with nonmutated
BRAF. Poorer OS was also demonstrated for those patients
with earlier stage II and III CRC having a BRAF mutation8,54;
however, the poorer outcome appears to be primarily the
result of decreased OS after relapse in these patients rather
than a harbinger of an increased rate of relapse. Finally, while
outcomes in advanced disease patients with BRAF mutations
were poorer relative to nonmutation patients, the data were
consistent with a modest beneficial impact from the use of
anti-EGFR agents relative to those patients whose tumors
contained a RAS mutation.55 In summary, patients with CRC
that contains a BRAF mutation have a worse outcome relative
to nonmutation patients. Selected patients for BRAF mutation
testing include patients with metastatic disease, since these
patients have particularly poor outcomes. It is important to
know the BRAF c.1799 (p.V600) mutation status of a
patient’s CRC since standard therapy is not adequate for
patients with metastatic disease and BRAF mutation. For
these patients, some studies suggest the use of FOLFIRINOX
(folinic acid [leucovorin calcium], 5-fluorouracil, irinotecan
hydrochloride, and oxaliplatin) as first-line therapy, followed
by enrollment in a clinical trial.56 Furthermore, early clinical
trials data suggest that the combination of a BRAF plus EGFR
inhibitor appears to be effective in this population.57-59 Data
in support of molecular testing for BRAF c.1799 (p.V600)
mutations in CRC continue to emerge from clinical trials. A
recent publication of the PETACC-8 (oxaliplatin, fluoroura-
cil, and leucovorin with or without cetuximab in patients
with resected stage III colon cancer randomised phase 3)
trial reported that trials in the adjuvant setting should
Table 8 (cont)
Author,
Year
Study Type
and Evidence Comparison Tests Used
Codons
Studied OS PFS ORR
Yuan
et al,48
2013
SR: 21 studies
including
5,229
patients
Mutþ vs
Mut–
NR V600E HR, 0.35 (95%
CI, 0.29-0.42;
P < .05) in
favor of BRAF
Mut–
HR, 0.38 (95%
CI, 0.29-0.51;
P < .05) in
favor of BRAF
Mut–
RR, 0.31 (95% CI,
0.18-0.53;
P < .05) in favor
of BRAF and
KRASMut–
Xu et al,47
2013
SR: 19 studies
including
2,875
patients
Mutþ vs
Mut–
NR V600E,
K601E (1
study),
D549C (1
study)
HR, 2.85 (95%
CI, 2.31-3.52;
P < .05) in
favor of BRAF
Mut–
HR, 2.98 (95%
CI, 2.07-4.27;
P < .05) in
favor of BRAF
Mut–
ORR, 0.58 (95% CI,
0.35-0.94;
P < .05) in favor
of BRAFMut–
Prospective cohort studies (n¼1)
Etienne-
Grimaldi
et al,45
2014
251 patients Mutþ vs
Mut–
NR BRAF
p.V600E
NR Shorter RFS in
KRASMut–
and BRAF
Mut– patients
with stage III
tumors
(P < .05)
Retrospective cohort studies (n¼1)
Bando
et al,43
2013
82 samples
from 376
patients
All Mut- vs
BRAF
Mutþ and
PIK3CA
Mut–
Luminex xMAP
vs DS (concord-
ance rate
100%)
600 All Mut–: 13.8
months (95%
CI, 9.2-18.4)
vs BRAF/
PIK3CAMut:
6.3 months
(95% CI, 1.3-
11.3; P < .05)
All Mut–: 6.1
months (95%
CI, 3.1-9.2) vs
BRAF/PIK3CA
Mutþ: 1.6
months (95%
CI, 1.5-1.7;
P < .05)
All Mut–: 38.8% vs
BRAF/PIK3CA
Mutþ: 0%,
P < .05
BRAF, proto-oncogene B-Raf/v-Raf murine sarcoma viral oncogene homolog B; CI, confidence interval; CPG, clinical practice guideline; CRC, colorectal cancer; CT, chemo-
therapy; DS, direct sequencing; EGFR, epidermal growth factor receptor; HR, hazard ratio; KRAS, Kirsten rat sarcoma viral oncogene homolog; mAbs, monoclonal antibodies;
mCRC, metastatic colorectal cancer; MLH1, mutL homolog 1; Mut–, mutation negative or wild type; Mutþ, mutation positive; NR, not reported; ns, nonsignificant; ORR, objec-
tive response rate; OS, overall survival; PCR, polymerase chain reaction; PFS, progression-free survival; PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subu-
nit alpha; RR, response rate; RFS, recurrence-free survival; SR, systematic review; xMAP, multiplex assay.
aYang et al71: adenovirus-PCR pyrosequencing, allele-specific PCR, DS, PCR amplification, quantitative PCR, Sanger, real-time PCR, genotypingþDS, PCR clamping, melting
curve analysis, DNA sequencing, and Taqman single-nucleotide polymorphism assay.
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consider mismatch repair, BRAF, and KRAS status for strati-
fication, since BRAF p.V600 and KRAS mutations were
associated with shorter DFS and OS in patients with
microsatellite-stable colon cancer but not in those with
tumors with MSI.60,61
This recommendation is supported by seven systematic
reviews,20,47,48,50-53 three of which included meta-analy-
sis.47,48,53 None of the systematic reviews reported the com-
position of their panel, so multidisciplinary panel
representation could not be confirmed, and none reported
patient representation on the panel. All but the systematic
review reported by Baas et al20 reported examining impor-
tant patient subgroups. All of the systematic reviews
reported well-described and reproducible methods. Three
did not report how conflicts of interest were managed and
reported on.47,51,53 Only two reported on a quality assess-
ment of the included literature,48,50 and only one rated the
strength of the evidence.50 None reported a plan for updat-
ing. While none of the systematic reviews reported industry
funding, one study did not report any funding support.47
Overall, the risk of bias assessment for this body of evidence
ranged from low48,50 to moderate,20,51,53 and none were
found to have methodologic flaws that would raise concerns
about their findings.
2b. Recommendation: BRAF p.V600 mutational anal-
ysis should be performed in dMMR tumors with loss of
MLH1 to evaluate for Lynch syndrome risk. Presence of a
BRAF mutation strongly favors a sporadic pathogenesis.
The absence of BRAF mutation does not exclude risk of
Lynch syndrome.
dMMR occurs via several mechanisms. In sporadic
CRC, dMMR is most frequently caused by epigenetic
silencing through CpG methylation primarily of MLH1,
with few cases resulting from somatic mutation of one of
the MMR genes. In Lynch syndrome CRC, the underlying
mechanism is usually a germline mutation of one of the four
(MLH1, MSH2, MSH6, and PMS2) mismatch repair genes
and, in rare patients, a deletion involving EPCAM (epithe-
lial cell adhesion molecule), a gene adjacent to MSH2, that
leads to epigenetic inactivation of the MSH2 gene. dMMR
occurs in 15% to 20% of all colorectal cancers, and of these,
about three-fourths are due to MLH1 epigenetic
silencing.5,62 dMMR underlies widespread mutations in the
genome and MSI. BRAF p.V600 mutations rarely occur in
patients with germline-based dMMR but have been reported
in up to three-fourths of those with epigenetic MMR gene
silencing (Table 8 and Table 9 ). Thus, testing for BRAF
mutations serves as a means for distinguishing germline
from epigenetic dMMR, particularly in those cases where
the dMMR is the result of epigenetic silencing of MLH1.
For tumors with a mutation in BRAF and dMMR, it may be
concluded that the basis for their dMMR is less likely to be
germline.5,52,62 In contrast, tumors with dMMR in the
absence of a BRAF mutation may have either germline or an
epigenetic (MLH1 gene promoter hypermethylation) basis
for the dMMR, and specific testing for MLH1 promoter
hypermethylation may be used to further refine the risk of
Lynch syndrome before initiating definitive genetic testing.
Identification of those patients with germline-based dMMR
has clear implications for the patient’s family members.
3. Recommendation: Clinicians should order mis-
match repair status testing in patients with colorectal can-
cers for the identification of patients at high risk for Lynch
syndrome and/or prognostic stratification.
The molecular pathology underlying most MSI tumors
is somatically acquired CpG methylation of the promoter of
the gene, MLH1. About three-fourths of colorectal cancers
with MSI due to MLH1 promoter hypermethylation will
have an acquired BRAF mutation as well. The reason for
this is not understood. Less than one-third of individuals
Table 9
Summary of Frequencies of Tumor V600E Mutation Statusa
Sample Group No. of Studies Positive p.V600E, No. Negative BRAF p.V600E, No. BRAF p.V600E,% (95% CI)
Known negative MMR mutation
status
MSI-H known mutation status 11 115 216 36.10 (20.95-52.84)
MLH1methylation orMLH1
loss of expression (known or
assumes MSI-H status)
9 191 141 63.50 (46.98-78.53)
MSS 11 85 1,538 5.00 (3.55-6.68)
Known positive MMR mutation
status
All mutation carriers 26 4 546 1.40 (0.06-2.25)
BRAF, proto-oncogene B-Raf/v-Raf murine sarcoma viral oncogene homolog B; CI, confidence interval; MMR, mismatch repair; MSI-H, microsatellite instability high; MLH1,
mutL homolog 1; MSS, microsatellite stable.
aAdapted from Parsons et al52 by permission from BMJ Publishing Group Limited.
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with dMMR/MSI colorectal tumors do not have underlying
MLH1 promoter hypermethylation but rather have a germ-
line mutation affecting any one of the four DNA MMR
genes noted above. Individuals with germline mutations in
the MMR genes are said to have Lynch syndrome, an auto-
somal dominant disorder that confers dramatically increased
risks for colorectal and endometrial cancers and moderately
increases risks for a variety of other tumors.63 Diagnosis of
Lynch syndrome is important as active management of can-
cer risks has been demonstrated to benefit gene mutation
carriers,5,64,65 and establishing a diagnosis creates opportu-
nities for prevention among all at-risk relatives. Testing for
dMMR can be performed by immunohistochemistry for the
four MMR proteins (MLH1, MSH2, PMS2, and MSH6) or
by MSI DNA-based testing, as discussed in detail in a report
by Funkhouser et al66 (recommendation 11).
A systematic review of 31 studies7 reporting survival on
12,782 patients whose tumors were characterized for MSI
showed a favorable prognosis, as determined by both OS and
DFS Table 10 , but this is dependent on stage. In addition, the
presence of MSI in CRC was reported to be predictive for non-
response to 5-fluorouracil–based adjuvant chemotherapy of
early stage disease,6 although this has not been corroborated
(Table 10).67 Emerging data indicate that MMR status may
have predictive value in some settings, specifically in patients
with advanced disease being considered for anti-programmed
cell death protein-1 (PD-1)/ programmed cell death ligand
protein-1 (PD-L1) immune checkpoint inhibitor therapy.68-70
This recommendation is supported by two systematic
reviews that included 38 studies and 16,472 patients.6,7
Both of these systematic reviews included a well-described
and reproducible methods section, and both reported on
potential conflicts of interest. Only one, the systematic
review reported by Guastadisegni et al,7 reported the source
of funding, which was nonindustry. Due to deficits in the
reporting, one of these systematic reviews was deemed to
have a moderate risk of bias,6 and the other was deemed to
have a low to moderate risk of bias7; however, neither of
these were found to have any major methodologic flaws that
would cause us to question their findings.
4. No Recommendation: There is insufficient evidence
to recommend BRAF c.1799 (p.V600) mutational status as a
predictive molecular biomarker for response to anti-EGFR
inhibitors.
As noted in recommendation 2a, mutations in position
p.V600 in BRAF are associated with poor prognosis, espe-
cially in patients with metastatic disease. Response rates to
chemotherapy regimens, including regimens with cetuxi-
mab and panitumumab, are lower in patients harboring
BRAF p.V600 mutations51,53,71 (Table 8). Similarly, the
PFS and OS after treatment with EGFR monoclonal anti-
bodies in combination with chemotherapy are lower in
patients with BRAF p.V600 mutations.47,48 Many of these
analyses used nonrandomized cohorts, thereby making eval-
uation of the potential predictive value of the BRAF p.V600
mutation impossible to discern (Table 8). In addition, the
poor prognosis and low mutation prevalence make evalua-
tion of the relative benefit of EGFR inhibitors difficult to
evaluate in individual randomized clinical trials.
Meta-analyses of randomized studies of EGFR mono-
clonal antibodies have been completed to address the ques-
tion of the predictive role of BRAF p.V600 mutations. A
meta-analysis of 463 patients with KRAS wild-type and
Table 10
Mismatch Repair/Microsatellite Instability Systematic Reviews
Author, Year
Study Type and
Evidence Comparison Tests Used OS PFS
Guastadisegni et al,7
2010
SR: 31 studies
including 12,782
patients with CRC
MSI vs MSS MSI by PCR in
all and IHC in
6 studies
OR, 0.6; 95% CI, 0.53-
0.69, P < .0001, MSI
is associated with
longer survival
DFS, OR, 0.58; 95% CI,
0.47-0.72, P < .0001,
MSI is associated with a
longer PFS duration
Des Guetz et al,6
2009
SR: 7 studies includ-
ing 3,690 patients
with CRC on
effect of adjuvant
chemotherapy
1,444 treated
with 5-FU–based
therapy and 1,518
not treated
MSI vs MSS PCR in all and
IHC in 2
studies
MSI-H: HR, 0.70; 95%
CI, 0.44-1.09, P ¼ ns;
no significant benefit
of chemotherapy in
MSI-H patients
MSI-H: RFS, HR, 0.96;
95% CI, 0.62-1.49, P ¼
ns; no significant differ-
ence if treated or not
treated MSI-H vs MSS:
RFS, HR, 0.77; 95% CI,
0.67-0.87, P < .05, MSI
patients had no effect of
treatment compared
with beneficial effect in
MSS patients
CI, confidence interval; CRC, colorectal cancer; DFS, disease-free survival; 5-FU, 5-fluorouracil; HR, hazard ratio; IHC, immunohistochemistry; MSI, microsatellite instability;
MSI-H, microsatellite instability high; MSS, microsatellite stable; ns, nonsignificant; OR, odds ratio; OS, overall survival; PCR, polymerase chain reaction; PFS, progression-
free survival; RFS, relapse-free survival; SR, systematic review.
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BRAF p.V600 mutated tumors did not provide sufficient
evidence to exclude a magnitude of benefits seen in KRAS/
BRAF wild-type tumors. Nor was there sufficient evidence
to identify a statistically significant benefit to this
treatment.55 A second meta-analysis showed that EGFR
monoclonal antibody treatment in patients whose tumors
contain a BRAF p.V600 mutation was not associated with
significant OS (P ¼ .43), although there was a trend for bet-
ter PFS (P ¼ .07).72 This suggests insufficient evidence to
recommend the use of BRAF p.V600 as a predictive marker
for benefit of anti-EGFR monoclonal antibodies. More data
are required to definitively determine the predictive value of
BRAF mutations relative to anti-EGFR therapy.
This recommendation was supported by five systematic
reviews47,48,51,53,71 (Table 8). None of these systematic reviews
reported forming a multidisciplinary panel, and none reported
including patient representatives in developing their research
questions or interpreting their outcomes. All of the systematic
reviews examined important patient subtypes, and all used
well-described and reproducible methods. Only the systematic
review by Yuan et al48 reported on any potential conflicts of
interest, the article by Mao et al51 stated conflicts were not
examined, and the other three did not report anything regarding
conflicts.47,53,71 Only two, the systematic reviews reported by
Yang et al71 and Yuan et al,48 rated the quality of the included
evidence, although none of the studies reported on the strength
of the evidence. None of the studies discussed any plans for
future updating. Four reported nonindustry funding for their
systematic reviews,48,51,53,71 and one did not report the source
of funding, if any.47 Two of the systematic reviews were
deemed to have a low risk of bias,48,71 one was deemed to
have a low to moderate risk of bias,47 and two were deemed to
have a moderate risk of bias.51,53 Overall, none of the system-
atic reviews were found to have methodologic flaws that
would raise concerns about their findings.
5. No Recommendation: There is insufficient evidence
to recommend PIK3CA mutational analysis of colorectal car-
cinoma tissue for therapy selection outside of a clinical trial.
Note: Retrospective studies have suggested improved
survival with postoperative aspirin use in patients whose
colorectal carcinoma harbors a PIK3CA mutation.
Despite comprehensive RAS testing (recommendation
1), many patients still fail to respond to EGFR monoclonal
antibody therapy. Additional biomarkers to guide patient
selection for such therapy are desired.
PIK3CA mutations are observed in 10% to 18% of
patients with CRC, primarily in exons 9 and 20, and lead to a
constitutive activation of p100a enzymatic activity, leading
to an increased PI3K activity and high oncogenic transforma-
tion ability. However, mutations of KRAS or NRAS and
PIK3CA mutations can be detected alternatively and, in some
cases, concurrently in a single CRC.3,8 PIK3CA mutations
are positively correlated with KRAS exon 12 and 13 muta-
tions.3 Several meta-analyses and one individual patient data
large pooled analysis have examined the prognostic role of
PIK3CA in patients with stage IV CRC, both overall and in
the KRAS nonmutated/wild-type population. These studies
have generally indicated poorer response rate and PFS in
patients with the PIK3CA mutation, a finding that appears to
be driven primarily by patients with exon 20 mutation3,33,50,71
Table 11 . These meta-analyses have included many of the
same studies, as well as observed and acknowledged
between-study heterogeneity, and all have concluded further
prospective data are necessary. Contradictory recent studies
have also been recently reported.74 None of the studies con-
sidered the independent role of PIK3CA in the context of
comprehensive RAS testing. De Roock et al3 estimated that
comprehensive PIK3CA testing would increase response rate
in the first-line setting by only 1%. The prognostic impact of
PIK3CA in stage I to III disease has been inconsistent.75-77
Multiple prospective observational studies have demon-
strated an association between aspirin use and decreased
CRC mortality.78-80 Data on aspirin as a treatment for CRC
(postdiagnosis usage) are more limited and drawn only from
observational studies. Domingo et al81 and Liao et al82
found a survival advantage for posttreatment aspirin users
only in patients whose tumors exhibit PIK3CA mutations;
however, a recent cohort study did not validate these obser-
vations.83 Multiple prospective studies are under way to
address the potential benefit of adding aspirin or other non-
steroidal anti-inflammatory drugs to adjuvant therapy.
This recommendation is supported by two systematic
reviews33,40 obtained from our systematic review. None
reported the composition of a multidisciplinary panel,
reported patient representation or study quality, rated
strength of the evidence reviewed, or disclosed a plan for
updating. However, both systematic reviews did include rel-
evant patient subgroups and included methods that were
well described and reproducible. In both systematic reviews,
information about the potential conflicts of the panelists
was reported, and funding was provided by nonindustry
sources. Both were found to have a moderate risk of bias,
but neither of the studies providing the evidence base for
recommendation 5 were found to have methodologic flaws
that would raise concerns about their findings.
At the present time, the retrospective data for the use of
PIK3CA mutation to deny anti-EGFR antibody therapy in
patients with stage IV CRC or as a selection factor for use
of aspirin in stage I to III tumors are insufficient for clinical
use outside of a clinical trial.
6. No Recommendation: There is insufficient evidence
to recommend PTEN analysis (expression by
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immunohistochemistry [IHC] or deletion by fluorescence in
situ hybridization [FISH]) in colorectal carcinoma tissue for
patients who are being considered for therapy selection out-
side of a clinical trial.
PTEN functions as a tumor suppressor gene, and loss of
PTEN results in upregulation of the PI3K/AKT pathway.
PTEN mutations occur in approximately 5% to 14% of
colorectal cancers,4,84 and loss of PTEN expression can be
observed in tumors with KRAS, BRAF, and PIK3CA
mutations.
Although there is evidence suggesting that PTEN is a
critical factor in cancer development, the association
between PTEN expression and predictive/prognostic value
remains controversial, with several studies suggesting an
Table 11
PIK3CA Clinical Practice Guidelines, Systematic Reviews, Meta-Analyses, Prospective Cohort Studies, and Retrospective Cohort
Studies
Author, Year
Study Type and
Evidence Comparison Tests Used
Codons
Studied OS PFS ORR
CPGs, systematic reviews, and meta-analyses on PIK3CAMutþ vs Mut– (n¼5)
Wu et al,73
2013
SR: 8 839
patients with
mCRC who all
received anti-
EGFR mAbs
Mutþ vs Mut– Sanger, allelic dis-
crimination,
direct sequenc-
ing,
pyrosequencing
Exons 9, 20 HR, 1.28; 95% CI,
1.05-1.56, P <
.05, patients
with PIK3CA
Mutþ had
shorter PFS
PFS, HR, 1.53;
95% CI, 1.28-
1.84, P < .05,
patients with
PIK3CAMutþ
had shorter
PFS
NR
Mao et al,33
2012
SR: 13 studies
including
patients all
KRASMut–
treated with
anti-EGFR
mAbs
E20 Mutþ vs
E20 Mut–
NR Exon 20 HR, 3.29; 95% CI,
1.60-6.74;
P < .05
PFS, HR, 2.52;
95% CI, 1.33-
4.78, P < .05,
PIK3CA exon
20 mutations
associated
with shorter
PFS
ORR%: Exon 20
Mutþ: 0; Exon
20 Mut–: 37%
RR, 0.25; 95%
CI, 0.05-1.19,
P ¼ ns (subset:
377 patients)
Lin et al,50
2011
SR: 4 studies
1,030 patients
with mCRC,
all KRASMut–
subgroup anal-
ysis, exons 9
and 20
Mutþ vs Mut– NR Exons 9, 20 P ¼ ns, no differ-
ence between
Mutþ and Mut–
patients Exon
20 Mutþ pre-
dicts poorer
survival
P ¼ ns, no differ-
ence between
Mutþ and
Mut patients
Exon 20 Mutþ
predicts
poorer survival
NR
Baas et al,20
2011
SR: 3 studies
including 195
patients with
mCRC
Mutþ vs Mut– Sequencing,
pyrosequencing
Exons 9, 20 NR NR NR
Yang et al,71
2013
SR: 10 studies
(patient num-
ber ¼ NR)
Mutþ vs Mut– DS, PCR amplifica-
tion, AS-PCR,
genotyping, RT-
PCR, Sanger,
DNA sequenc-
ing,
pyrosequencing
Exons 7, 8, 9,
18, 19, 20
(6 studies) HR,
1.43 (95% CI,
1.02-2.0; P <
.05) in favor of
Mut–
(6 studies) HR,
1.91 (95% CI,
0.78-4.68; P ¼
ns) P < .05 in
favor of exon
9 compared
with exon 20
mutations
(6 studies) RD:
–23% (-35%,
-10%; P < .05)
in favor of exon
9 compared
exon 20
mutations
Retrospective cohort studies (n¼1)
Bando et al,43
2013
82 samples from
376 patients
All Mut– vs
BRAFMutþ
and PIK3CA
Mutþ
Luminex xMAP vs
DS (concord-
ance rate 100%)
Exon 9 All Mut–: 13.8
months (95%
CI, 9.2-18.4) vs
BRAF/PIK3CA
Mutþ: 6.3
months (95%
CI, 1.3-11.3;
P < .05)
All Mut–: 6.1
months (95%
CI, 3.1-9.2) vs
BRAF/PIK3CA
Mutþ: 1.6
months (95%
CI, 1.5-1.7;
P < .05)
All Mut: 38.8%
vs BRAF/
PIK3CAMutþ:
0, P< .05
AS-PCR, allele-specific polymerase chain reaction; CI, confidence interval; CPG, clinical practice guideline; DS, direct sequencing; EGFR, epidermal growth factor receptor;
HR, hazard ratio; mAbs, monoclonal antibodies; mCRC, metastatic colorectal cancer; Mut–, mutation negative or wild type; Mutþ, mutation positive; NR, not reported; ns, non-
significant; ORR, objective response rate; OS, overall survival; PCR, polymerase chain reaction; PFS, progression-free survival; PIK3CA, phosphatidylinositol-4,5-bisphosphate
3-kinase catalytic subunit alpha; RD, risk difference; RR, response rate; RT-PCR, reverse transcription polymerase chain reaction; SR, systematic review; xMAP, multiplex
assay.
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association with poorer prognosis and others finding no
association at all. Four systematic reviews were obtained
that reported on loss of PTEN expression compared with
normal PTEN expression and 31 primary studies, includ-
ing a total of 2,545 patients20,50,85,86 (Supplemental Table
14). Tests used included IHC and FISH. Of the four stud-
ies that reported overall survival rates,20,50,85,86 three
studies reported on pooled outcomes.50,85,86 One study
reported a significant difference in favor of normal PTEN
expression,86 and the others reported no significant
differences.20,50,85 For PFS, three studies pooled
outcomes,50,85,86 two detected a significant difference in
favor of normal PTEN expression,85,86 and one showed
no significant difference.50 For ORR, two studies pooled
outcomes, and both found loss of PTEN expression asso-
ciated with a poorer response.85,86
Several studies have shown an association between
PTEN loss and local recurrence, advanced TNM stage,
lymph node metastasis, and a lower 5-year survival rate.87-
90 However, several other studies have found no correlation
between PTEN status and patient survival, tumor grade,
TNM stage, lymphatic invasion, and liver metastasis.91-93
Regarding response to EGFR-targeted therapies, several
studies have shown an association with PTEN loss and lack
of response to cetuximab and panitumumab.94-97 However,
other published studies failed to demonstrate a clear correla-
tion between loss of PTEN expression and response to anti-
EGFR therapy.98-100 Given the significant discordance in
results, the role of PTEN as a prognostic or predictive bio-
marker in CRC is still largely unknown, and research into
the prognostic and predictive significance of PTEN is
ongoing.
This recommendation is supported by 20 stud-
ies,4,20,50,84-100 four20,50,85,86 of which met the inclusion cri-
teria for inclusion in our systematic review. All four of these
were systematic reviews and included 42 studies and 3,412
patients. None of these systematic reviews reported using a
multidisciplinary panel or reported including the patient
perspective or a plan for future updating. Three50,85,86
reported on important patient subgroups. All four had well-
described and reproducible methods sections. Three20,50,86
reported that potential conflicts of interest were examined.
Only two50,86 rated the quality of the included evidence, and
these same two were also the only two that rated the strength
of the evidence. Only three20,50,86 reported on the source of
any funding, but all three reported nonindustry funding. One
was deemed to have a low risk of bias,50 one was deemed to
have a low to moderate risk of bias,86 and two were deemed
to have a moderate risk of bias.20,85 None of the studies
were found to have any methodologic flaws that would
bring doubt to their findings.
7. Expert Consensus Opinion: Metastatic or recurrent
colorectal carcinoma tissues are the preferred specimens for
treatment predictive biomarker testing and should be used if
such specimens are available and adequate. In their absence,
primary tumor tissue is an acceptable alternative and should
be used.
In clinical practice, one or more specimens of CRC
from an individual patient may become available for molec-
ular testing during the course of the disease. These speci-
mens may include initial diagnostic biopsy or surgical
resection specimens of the primary tumor and resection,
biopsy, or cytologic specimens from metastatic and recur-
rent tumor. Discordance between primary and metastatic
lesions may be attributed to a number of mechanisms,
including tumor heterogeneity already present in the pri-
mary tumor, tumor evolution, where novel mutations are
acquired, and, in some cases, the presence of separate pri-
maries. The systematic literature review for the CRC guide-
line was done to identify studies that compared the
mutational status of primary vs metastatic CRC.
An earlier systematic literature search that was con-
ducted to include studies testing concordance of KRAS,
BRAF, PIK3CA, and loss of PTEN expression in CRC20
reported the results of 21 studies, with an overall con-
cordance rate of 93% (range, 76%-100%) for KRAS, 93%
for BRAF status, a range of 89% to 94% for PIK3CA, and
68% for loss of PTEN. Table 12 shows the summary of
two subsequent studies where KRAS, NRAS, BRAF, and
PIK3CA mutation and PTEN expression were compared
in paired primary vs metastatic tumor lesions.101,102
Overall concordance rates between primary and meta-
static lesions were high with more than 90% concordance
(Table 12).101,102 In the study by Lee et al, analysis of
Table 12
Concordance Rates Between Primary and Metastatic Lesionsa
Genes Tested (n) Concordance Rate,%
KRAS (117)101 91.0
KRAS, NRAS, BRAF (84)102 98.8
PIK3CA (117)101 94.0
PIK3CA (84)102 92.8
PTEN IHC (117)101 66.0
aSummary of two randomized clinical trials where comparison of mutation in KRAS,
NRAS, BRAF, and PIK3CA was performed for paired primary tumor and metastatic
lesions. Immunohistochemistry for PTEN was done in Cejas et al.101 In the study by
Cejas et al,101 metastases were synchronous or metachronous. DNA was extracted
from formalin-fixed, paraffin-embedded tissue, and mutational analysis was per-
formed with a polymerase chain reaction–direct sequencing assay. KRAS mutations
were detected in 42% of metastatic lesions and 39% of primary tumors. In the study
by Vakiani et al,102 DNA was extracted from frozen tissue, and the iPLEX (Agena
Bioscience, San Diego, CA) assay was used to examine the following mutations:
KRAS 12, 13, 22, 61, 117, and 146; NRAS 12, 13, and 61; BRAF 600; and PIK3CA
345, 420, 542, 545, 546, 1043, and 1047.
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KRAS mutation in primary and recurrent tumors after rad-
ical resection showed 20.3% discordance.103
This recommendation was supported by two retrospec-
tive cohort studies101,102 that were obtained in the system-
atic review. Both of these studies compared results within a
single cohort. The study reported by Cejas et al101 reported
at least partial industry funding, and the study reported by
Vakiani et al102 did not report the source of funding, if any.
The study by Cejas et al101 was deemed to have a low to
moderate risk of bias, and the study by Vakiani et al102 was
deemed to be low. Overall, neither of these studies had any
methodologic flaws that would raise concerns about the
reported findings.
In summary, given that discordance of mutational status
between primary and metastatic or recurrent CRC lesions
may occur in a number of cases, metastatic or recurrent
CRC tissues are the preferred specimens for treatment pre-
dictive biomarker testing. However, if these specimens are
not available, primary tumor tissue is an acceptable alterna-
tive, given the overall high rates of concordance for the
mutation status of EGFR pathway genes.
8. Expert Consensus Opinion: Formalin-fixed, paraf-
fin-embedded (FFPE) tissue is an acceptable specimen for
molecular biomarker mutational testing in colorectal carci-
noma. Use of other specimens (eg, cytology specimens) will
require additional adequate validation, as would any
changes in tissue-processing protocols.
The systematic review identified a number of studies,
summarized in Table 13 , where CRC KRAS mutational
testing was performed using FFPE specimens as well as
fresh or frozen specimens. Recommendation 17 highlights
the importance of review of stained sections of tumor
selected for testing by a pathologist to verify the tumor cell
content population of the sample and demarcate regions for
potential macrodissection or microdissection to enrich for
cancer cells. Biopsy and resection specimens are similarly
acceptable, as long as sufficient tumor cells are present
(Table 13). Cytology specimens may be adequate for testing
but will require proper validation. The use of FFPE cell
blocks allows for the evaluation of tumor cell content and
viability.104 Laboratories will need to establish the mini-
mum tumor cell content for specimens based on the per-
formance characteristics of their validated assay.105,126
Liquid biopsy tests use serum or plasma and may be
used for monitoring tumor recurrence and emergence of treat-
ment resistance. The noninvasive nature of this approach
(monitoring through blood testing) offers great potential for
clinical use.106 However, at the present time, the clinical
application of liquid biopsy assays awaits robust validation
and further studies to determine their clinical utility.
9. Strong Recommendation: Laboratories must use
validated colorectal carcinoma molecular biomarker testing
methods with sufficient performance characteristics for the
intended clinical use. Colorectal carcinoma molecular bio-
marker testing validation should follow accepted standards
for clinical molecular diagnostics tests.
Clinical validation assesses the molecular biomarker
testing method in light of clinical characteristics of the
disease or marker being tested, to ensure the test is “fit
for purpose.” Elements of clinical validation include ana-
lytical sensitivity, analytical specificity, clinical sensitiv-
ity, and clinical specificity. Data for clinical validation
can be obtained from studies performed by the laboratory,
studies reported in peer-reviewed literature, or other reli-
able sources. CLIA requires clinical laboratories to have a
qualified laboratory director who is responsible for ensur-
ing that the laboratory provides quality laboratory services
for all aspects of test performance.107 Rigorous validation
should be performed to ensure all molecular marker test-
ing methods, such as those used for colorectal carcinoma,
are ready for implementation in the clinical laboratory. To
reach that goal, each step of the testing process must be
carefully evaluated and documented. Excellent and com-
prehensive documents have been published on this topic,
and a detailed review is provided under recommendation
10. Our systematic review of the available literature pro-
vided information regarding the performance characteris-
tics of molecular marker testing methods of colorectal
carcinoma in clinical use for RAS mutational testing
(Table 13). Most studies reported the performing charac-
teristic of assays that detected KRAS exon 2 mutations, as
detailed in Table 13. Direct sequencing of genomic DNA,
even after polymerase chain reaction (PCR) amplification
of the fragment of interest, has low analytical sensitivity
requiring a mutant allele frequency of about 20% for
mutation detection. A number of more sensitive assays
have been developed for RAS testing, including those
listed in Table 13.
Sanger sequencing was used as the most common base-
line assay for comparison against other molecular detection
methods for KRAS mutations. Testing methods vary widely,
including direct Sanger sequencing, amplification refractory
mutation system, real-time PCR–high-resolution melting
(HRM) assays, allele-specific PCR, Luminex (Austin, TX)
bead microarray, PCR restriction fragment length poly-
morphism strip assays, pyrosequencing, and, more recently,
NGS. Population or clinical sensitivity of the testing meth-
ods for KRAS mutations as shown in Table 13 ranged
between 36% and 59%. Assay sensitivity ranged from
84.4% to 100%, with Sanger sequencing on the lower end of
the range. Analytical sensitivity, defined as the lowest
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detectable mutant allele fraction, was between 0.5% and
20% across all testing methods, with most methods perform-
ing between 1% and 5% mutant allele fraction. Specificity
was between 98% and 100% for most assays, with two stud-
ies demonstrating lower specificity. Positive predictive
value percentages varied between 66% and 100%, with most
studies reporting between 99% and 100%. Negative predic-
tive value percentages were between 97% and 100%.
Minimal tumor percentages reported varied widely between
studies. Concordance between assays was between 93% and
100%, with some variability noted in two retrospective
cohort studies. The available evidence from assays to detect
KRAS mutations supports the use of a number of alternative
assays, as long as their performing characteristics, adjusted
for sample type and percent tumor purity, meet the clinical
sensitivity with acceptable specificity. Recently, NGS has
been used in a number of studies and in laboratory practice
for solid tumor mutational analysis.108 NGS has shown to
meet the sensitivity of detection used in CRC clinical tri-
als (detecting at least 5% mutant alleles), permitting
simultaneous testing of hundreds of mutations, and is
becoming widely used. Testing for mutations in multiple
genes or gene loci with multiplex assays such as NGS and
other methods should be done on patients at the time of
metastases to obtain comprehensive genomic information
and identify mutations beyond RAS/BRAF status that
might be able to be targeted if conventional therapies
become ineffective.
10. Strong Recommendation: Performance of molecu-
lar biomarker testing for colorectal carcinoma must be vali-
dated in accordance with best laboratory practices.
Proper validation of CRC biomarker testing is
important to ensure appropriate patient care. If validation
Table 13
Comparison of Test Performing Characteristic of Assays for KRASMutation Detection
Author, Year No. Comparison
Testing
Method Codons Tissue Site Procedure
Ma et al, 2009130 100 Sequencing HRM 12, 13 Primary NR
Pinto et al, 2011131 372 Consensusc Sequencing 12, 13 NR NR
184 DxS
182 HRM
372 Snapshot
Tol et al, 2010132 511 Sequencing DxS 12, 13 Primary Resection
Buxhofer-Ausch et al, 2013133 60 Sequencing SA 12, 13 Primary NR
Chang et al, 2010136 60 Sequencing MPCR PE 12, 13, 61 Primary NR
Chen et al, 2009137 90 Sequencing SSCP 12, 13 Primary NR
Chow et al, 2012138 204 Sequencing ASP 12, 13 NR NR
Sundstrom et al, 2010142 100 DxS Pyro 12, 13, 61 Primary or met Biopsy
Franklin et al, 2010128 59 Sequencing HRM 12, 13 Primary Resection
59 Sequencing ARMS 12, 13 NR
Laosinchai-Wolf et al, 2011129 86 Sequencing BMA 12, 13 Primary NR
Carotenuto et al, 2010134 540 Sequencing DxS 12, 13 Primary NR
540 Sequencing Sanger
Cavallini et al, 2010135 112 DxS SA 12, 13 NR NR
112 DxS PCR-RFLP
Kristensen et al, 2010139 61 COLD-PCR DxS 12, 13 Primary Resection
61 PCR MCA
Kristensen et al, 2012140 100 CADMA DxS 12, 13 Primary Resection
100 DxS CADMA
Lang et al, 2011141 125 Sequencing ASP 12, 13 Primary Resection
ARMS, amplification refractory mutation system; ASP, allele specific (nonquantitative); BMA, Luminex bead microarray; CADMA, competitive amplification of differentially
melting amplicons; COLD-PCR, coamplification at lower denaturation temperature-PCR; DxS, QIAGEN method; FFPE, formalin fixed, paraffin embedded;
HRM, high-resolution melting; M, missing; MCA, melting curve analysis; met, metastatic; MPCR PE, multiplex polymerase chain reaction (KRAS, NRAS, HRAS) and primer
extension; NPV, negative predictive value; NR, not reported; PPV, positive predictive value; PCR-RFLP, polymerase chain reaction–restriction fragment length polymorphism;
PCS, prospective cohort study; Pyro, pyrosequencing; RCS, retrospective cohort study; SA, KRAS-BRAF strip assay; SSCP, single-strand conformation polymorphism.
aPopulation or clinical sensitivity of testing method (%) of cases positive for KRAS mutation tested.
bFour (9.5%) of 42 samples negative for KRAS mutation by direct sequencing were positive for KRAS mutations by HRM analysis.
cTotal of 84.4% of consensus mutation result.
dDetected one mutation in 23 Mut– alleles.
eVariable concordance for different tumor percentage in the sample.
fThe sensitivity was increased by 5- to 100-fold for melting temperature decreasing mutations when using COLD-PCR compared with standard PCR. Mutations, undetectable
by the TheraScreen (QIAGEN, Valencia, CA) kit in clinical samples, were detected by COLD-PCR followed by HRM and verified by sequencing. Sequencing (PCR of fragment
of interest followed by sequence analysis) described as direct sequencing.
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is inadequate, this can lead to erroneous results and
improper diagnosis, prognosis, and/or therapeutic inter-
vention. For example, with regard to RAS testing, a
false-positive result would lead to an improper withhold-
ing of therapy, whereas a false-negative result would
lead to distribution of an ineffective therapy, resulting in
increased costs and unnecessary side effects. As molecu-
lar oncology testing grows more complex with NGS,
thorough and proper validation of preanalytical (speci-
men type and processing), analytical (assay perform-
ance), and postanalytical (bioinformatics, annotation, and
reporting) steps is imperative.109,110
The design of a validation study somewhat depends on
the analyte (gene), mutations, or molecular alterations
assessed and chosen platform and technology. However,
assay validation should be done using best laboratory practi-
ces in accordance with CLIA (42 CFR 493.1253(b)(2), also
known as Title 42 Chapter IV Subchapter G Part 493
Subpart K§493.1253)111 as applicable to the assay type.
Laboratories should comply with CLIA and their individual
accrediting agency (eg, CAP, New York State) to fulfill
requirements for validation.111,112 Additional resources for
establishing clinical molecular testing are available to assist
laboratories.113 For the US Food and Drug Administration
(FDA)–cleared/approved assays (without any modification),
verification of test specifications, including accuracy,
precision, reportable range, and reference range, only
needs to be done.114 For nonwaived, non–FDA-approved
assays (laboratory-developed procedures or LDPs), vali-
dation must be performed. Validation design must include
the required elements of analytical accuracy (specificity
and sensitivity), precision, and analytical sensitivity
(limit of detection) and interfering substances and report-
able range as applicable. Clinical sensitivity and specific-
ity, as well as positive and negative predictive value,
should be considered additions.
Additional considerations should include specimen
processing (including microdissection or macrodissection,
histologic processing, and fixation times) and reagent stabil-
ity and storage. Proper controls should be introduced and
used to assess as many of the potential mutations detected
by the assay and to verify the limit of detection identified in
the validation. With high-throughput (NGS) sequencing,
assessing all possible mutations through control material
and specimens is impossible, and continuing validation may
need to occur. If NGS is used, bioinformatics pipelines
should be properly validated using multiple types of muta-
tions (single-nucleotide variants and insertions/deletions).
Sample
Type
Population
Sensitivity of
Testing Method,%a
Sensitivity
of Assay
Analytical Sensitivity,
% (Mutant
Allele Fraction)
Specificity,
%
PPV,
%
NPV,
%
Minimal
Tumor,%
Concordance
Between
Assays,% Study
FFPE 59 Increasedb
(>100)
5-10 98 NR NR 30 95 PCS
FFPE 36.4 84.4c 15-20 NR NR NR >50 NR PCS
43.1 96 1 NR NR NR NR
42.7 98 3-10 NR NR NR NR
43.3 99 5 NR NR NR NR
Frozen 39.4 96.5 1 99.7 99.5 97.2 3-90 95.30 PCS
Biopsy 47.0 100 1 100 NR NR At least 50 100 PCS
Frozen 34.0 100 NRd 100 100 100 NR 100 PCS
Fresh 36.0 100 NR 100 100 100 NR 100 PCS
FFPE 40.7 100 1.25-2.5 100 100 100 NR NR PCS
39.0 91 1.25-2.5; 1.25 NR NR NR NR NR PCS
FFPE 54.0 100 1 87 81 100 1-90 NR RCS
43 100 5 71 66 100 1-90 93 RCS
FFPE 45.0 100 1 100 100 100 NR NR or M RCS
FFPE 38.6 95.8 1 100 100 97.3 <30 vs>70 Variablee RCS
98.6 NR 100 100 99.1 NR NR RCS
FFPE 92.5-100 NR 100 NR NR 70 NR RCS
92.5-100 NR 100 NR NR NR NR RCS
FFPE NR 93 0.1-5 100 NR NR NR f RCS
97 5-10 100 NR NR NR RCS
FFPE 44.4 98 0.50 98 NR NR NR 95.9 RCS
99 NR 100 NR NR NR NR RCS
FFPE 36.8 95.7e 1 NR NR NR >50 NR RCS
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Finally, reporting should be carefully considered during the
validation process. Resources to assist laboratories with
solid tumor molecular testing have also been made available
through the CLSI.115
Preanalytical Variables
Histologic or preanalytical processing should be con-
sidered and representative processes should be included in
the validation set. Specific specimen types should also be
properly validated. Most tissue used in CRC biomarker test-
ing is derived from FFPE tissue. Formalin fixation results in
fragmentation of DNA as a result of histone protein fixation
to the DNA. Therefore, most assays for FFPE tissue are
designed to amplify products less than 200 base pairs.
Length of formalin fixation and age of blocks may also be
factors to consider in validation of FFPE tissues. Other tis-
sue sources should also be separately validated if offered as
clinical tests, especially cytology-based specimens. Various
cytology fixative preparations should be validated as used
by the laboratory. If cell-free assays are considered, these
should be validated as a separate source. Finally, testing
should be limited to invasive carcinoma with exclusion of
adenomatous tissue and benign background tissue cellular
components (eg, normal mucosa, muscularis, inflammation)
as much as possible.
Analytical Variables
Careful specimen selection should be undertaken to
cover as many of the potential detected mutations and
expected specimen types as possible to ensure analytical
accuracy. A gold-standard method (dideoxy sequencing or
other validated test method) and/or interlaboratory compari-
son should be used to verify accuracy of the assay. For
example, the CAP Laboratory Accreditation Program
COM.40350 indicates that at least 20 specimens (including
positive, low-positive, and negative specimens) should be
included for qualitative and quantitative assays.112 More
specimens may be required. If it is a single-gene assay, the
design should include as many of the mutations covered by
the assay as possible. If it is a real-time–based allele-
specific assay, all mutations for which a primer probe reac-
tion is built should be analyzed as reasonably as possible. If
it is a pyrosequencing-based assay, similarly, all of the pos-
sible common mutations for which targeted therapies are
indicated should be tested. Multigene assays based on NGS
or other technology (such as SNaPshot [ThermoFisher
Scientific, Waltham, MA]) require an increased number of
specimens to test as many of the hotspot regions as possible
in all genes included in the assay. With such assays, not all
possible mutations can be validated. It is recommended that
an ongoing validation occur after initial validation, with ver-
ification of novel mutations by either dideoxy sequencing or
real-time PCR, depending on the laboratory capability and
limit of detection. Depending on the technology employed,
important parameters (eg, variant allele frequency, cyclic
threshold values, allele coverage) should be monitored for
interrun and intrarun precision.
CRC specimens can vary from large primary resection
blocks with plenty of tumor cells to small primary tumor or
metastatic CRC liver biopsy specimens to rectal specimens,
after neoadjuvant therapy with minimal tumor percentage.
Many of these tests are ordered for metastatic disease, for
which only a small needle core biopsy specimen or
cytologic sampling is available. Presently, tissue volume
and accessibility are decreasing while ancillary testing (IHC
and molecular studies) is increasing. The ability of an assay
to be highly analytically sensitive is important if a labora-
tory is to test specimens with low tumor burden. It is recom-
mended that an assay be able to identify a mutation in a
specimen that has at minimum 20% tumor cells (mutant
allele frequency of 10% assuming heterozygosity). With
NGS and highly sensitive PCR technologies, mutations
should be identifiable in specimens with as little as 10%
tumor (mutant allele frequency of 5% assuming hetero-
zygosity and diploidy). Lower analytically sensitive assays,
such as dideoxy sequencing, can be used, but it is recom-
mended that PCR enrichment strategies (eg, coamplification
at lower denaturation temperature-PCR) be used to increase
the analytical sensitivity of the test and require less tumor
percentage. A proper validation study should use cell line
DNA (preferably FFPE treated) or reference control mate-
rial manufactured by good manufacturing processes to
assess limit of detection for as many mutations as possible.
Importantly, the limit of detection may differ for mutations
of varying types (small indels vs point mutations).
Postanalytical Variables
Postanalysis is as important to consider in validation as
preanalytical and analytical variables. For single-gene
assays, the software used in analysis should be validated,
with verification of updates. If NGS is used, the bioinfor-
matics pipeline should be thoroughly and rigorously vali-
dated, include potential problematic mutations (eg, large
indels), and be verified or revalidated for new upgrades as
applicable to the change. Any analysis should be performed
on validation specimens as it would be for clinical
specimens.
Reporting format should also be considered and
decided during validation. Interpretation comments for
inclusion in the patient report to ensure that the reports are
correctly understood should be developed during the valida-
tion process.112 Human Genome Organisation (HUGO)–
based nomenclature should be used for reports and a desig-
nated National Center for Biotechnology Information
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(NCBI) transcript number (NM_##) should be used within
the validation and report.116 For multigene panels based on
NGS, reporting protocols and any used software should be
included in the validation procedure. Databases and annota-
tion guidelines should be discussed and included in the vali-
dation as one prepares to report variants based on NGS data.
In addition, decisions should be made during the validation
process as to whether normal tissue will be tested to assist in
variant interpretation with NGS.
In conclusion, validation of assays used in CRC molec-
ular testing is extremely important for accuracy of reporting
and proper patient care. There are several documents
(eg, CLIA, CAP, and CLSI)111-113,115 available to assist in
proper validation, which should be consulted to validate
according to best laboratory practices.
11. Strong Recommendation: Laboratories must vali-
date the performance of IHC testing for colorectal carci-
noma molecular biomarkers (currently IHC testing for
MLH1, MSH2, MSH6, and PMS2) in accordance with best
laboratory practices).
Four proteins (MLH1, MSH2, MSH6, and PMS2) are
currently considered important in the normal biochemistry
of DNA MMR.117-119 As detailed in recommendation 2b,
altered DNA mismatch repair proteins due to mutation or
epigenetic silencing result in interference with normal
MMR protein heterodimerization and loss of normal repair
of mispaired bases and short insertions/deletions, resulting
in MSI,119,120 overall categorized as dMMR. Loss of MMR
function usually correlates with loss of protein expression,
such that immunohistochemical testing for MMR proteins is
optimized to detect loss of MMR protein expression in
tumor cell nuclei. Each of these four proteins can be
detected in paraffin sections using commercially available
primary and secondary antibodies, standardized antigen
retrieval, and 3,30-diaminobenzidine chromogen detection.
Development of anti-MMR protein antibody staining proto-
cols follows a standard approach that involves (1) demon-
stration of absent background noise with secondary
antibody alone and (2) empirical optimization of the signal-
to-noise ratio by testing different antibody concentrations,
antigen retrieval buffers, and reaction conditions, taking
advantage of internal control cells, including lymphocytes,
stromal cells, and other nonneoplastic nuclei.
Validation of the final staining protocol is required
prior to implementation for clinical use. Peer-reviewed liter-
ature-based guidelines for validation and revalidation of
immunohistochemical tests have been defined as 14 recom-
mendations and expert consensus opinions.121 Concordance
with internal or external known comparator tests is required
to exceed 90%. Proficiency testing is a good approach to
confirm interlaboratory test reproducibility. Test result
concordance across laboratories implies accuracy of partici-
pant laboratory diagnosis.
Once the protocol is defined and validated for a given
primary antibody clone and antigen retrieval conditions, a
known positive external control (eg, tonsil) is routinely run
in parallel with each unknown. This demonstrates that the
MMR protein was detectable on that staining run and allows
trust in a loss of expression result in the unknown specimen.
Each of the four MMR proteins is expressed in nonneoplas-
tic tissue, in most lymphocytes, and overexpressed in germi-
nal centers, such that most colon block sections will also
have positive internal control staining.
Overall, validated immunohistochemical detection of
MMR proteins is a trustworthy method for identification of
loss of expression of individual MMR proteins in paraffin
sections of CRC. In most CRCs with high-level microsatel-
lite instability (MSI-H), the loss of DNA MMR protein
expression in tumor cell nuclei by immunohistochemical
detection is uniform throughout the tumor.122,123 Rare cases
of MSI tumors have been reported to show heterogeneous
staining.124 Loss of MMR protein expression usually corre-
lates with MSI, particularly for MSI-H tumors, and is indi-
cative of dMMR. If MSH2 or MLH1 shows loss of
expression due to loss of function, then their heterodimer
partners (MSH6 and PMS2, respectively) will also not be
expressed. In contrast, inactivation of MSH6 or PMS2
results in loss of expression of the individual MMR protein
MSH6 or PMS2, respectively.
Although loss of MMR protein immunoreactivity is
generally detected in dMMR CRC, normal immunoreactiv-
ity can be seen in up to 10% of dMMR cases125; therefore,
MSI DNA testing may be performed either stepwise or as a
concurrent test.
12. Expert Consensus Opinion: Laboratories must
provide clinically appropriate turnaround times and optimal
utilization of tissue specimens by using appropriate techni-
ques (eg, multiplexed assays) for clinically relevant molecu-
lar and immunohistochemical biomarkers of CRC.
Expediency in reporting of biomarker results for color-
ectal tumors is dictated primarily by two factors: need for
patient management decisions and, more generally, patient
anxiety. Consequently, results of such evaluations should be
available within a timeframe for the involved clinician to
relay this information to the patient. This need is com-
pounded by the patient’s need to receive a complete under-
standing of his or her diagnosis and treatment plans going
forward. A reasonable benchmark is that nonacute bio-
marker results be available to the treating physician within
10 working days of receipt in the molecular diagnostics lab-
oratory. This turnaround time has been recommended in
other guidelines for molecular tumor testing.105,126,127
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Ideally, the transitional time between test ordering, tissue
block selection, block retrieval, and shipment to the per-
forming laboratory should be included in the 10-day time-
frame. Consequently, laboratories should make every effort
to minimize delays in securing appropriate tissue blocks for
testing. Testing laboratories should make every effort to
minimize processing time and return of results.
The availability of tumor tissue for biomarker evalua-
tion is generally not limiting in most cases of resected CRC.
Occasionally, following neoadjuvant therapy, the amount of
residual tumor in resection specimens can be very small and
focal. Similarly, the amount of tumor tissue obtained by
biopsy or fine-needle aspiration procedures from primary or
metastatic foci can be very small and challenging to test for
the desired biomarkers. In such circumstances, available tis-
sue blocks should be sectioned judiciously, reserving suffi-
cient sections for testing by molecular methods or
immunohistochemical techniques, as deemed appropriate to
secure as accurate and informative an evaluation as
possible.
Test turnaround times for RAS testing in instances of
advanced stage tumors are dictated by the need to select and
initiate appropriate chemotherapy options. Ideally, such
information should be available either at the time of postop-
erative oncology evaluation, where decisions regarding
therapeutic options are entertained, or at the tumor boards
where patient treatment options are discussed. In some insti-
tutions, these discussions may occur in the week following
surgery or biopsy and probably no later than in the second
week following tissue diagnosis and staging. Here, too, a
timeframe of no more than 10 days would seem an appropri-
ate benchmark for biomarker result availability.
In exceptional circumstances, even shorter test turn-
around times may be called for. Occasional patients have
histories sufficiently suggestive of Lynch syndrome that
prompt consideration and discussion regarding extent of
surgery (ie, complete colectomy or prophylactic hysterec-
tomy in select affected patients). Efforts should be made in
such circumstances to obtain appropriate test results as rap-
idly as possible to allow for informed decision making.
MMR immunohistochemistry can be performed and
reported with a turnaround time of 48 hours or less, and in
the appropriate clinical context, a result of preserved expres-
sion of MMR proteins would argue against Lynch syn-
drome. Conversely, any loss of MMR protein expression
will need to be integrated with additional clinical informa-
tion, family history, and further testing such as BRAF muta-
tion, MLH1 methylation testing, and potential germline
genetic testing. Furthermore, DNA MMR status, performed
by MMR immunohistochemistry or by MSI DNA tests, as a
good prognostic biomarker for CRC overall, should be
available within the recommended 10 working day turn-
around time for test results.
13. Expert Consensus Opinion: Molecular and IHC
biomarker testing in colorectal carcinoma should be initi-
ated in a timely fashion based on the clinical scenario and in
accordance with institutionally accepted practices.
Note: Test ordering can occur on a case-by-case basis
or by policies established by the medical staff.
Molecular and IHC biomarker testing is increasingly
being used in patient management. Prognostic biomarkers
are being used for early stage disease to guide decisions on
the use of adjuvant chemotherapy. Such discussions require
the availability of tests in a timely manner, and delays in ini-
tiation of therapy have been associated with worse out-
comes.127 Predictive biomarkers, such as those for EGFR
monoclonal antibody therapy, should be initiated in a timely
fashion to guide chemotherapy options and long-term treat-
ment planning. Institutional policies and practices that
encourage the rapid initiation of appropriate molecular and
IHC marker testing should be encouraged. Such policies
may include reflexive ordering of molecular and IHC
markers as guided by the clinical scenario and incorporation
of testing initiation by multiple members of the multidisci-
plinary team, as noted in recommendation 15.
14. Expert Consensus Opinion: Laboratories should
establish policies to ensure efficient allocation and utiliza-
tion of tissue for molecular testing, particularly in small
specimens.
The number of molecular and immunohistochemical
tests becoming available that have a direct benefit to patient
care will continue to increase. Most of these tests are per-
formed on FFPE specimens, the most common preservation
technique, including pretreatment and posttreatment biop-
sies and resections (Table 13). Tissues from patients with
cancer should be processed according to established labora-
tory protocols, which include quality controls of preserva-
tion materials, tissue dissection, time to fixation, fixation
time, and processing.
Laboratory protocols need to include procedures for
handling small samples such as endoscopic or core biopsy
specimens and fine-needle aspirate samples of metastatic
lesions (eg, from liver or lung). Limiting the number of tis-
sue fragments per individual cassette is encouraged.
Established protocols may allow upfront ordering of
required tissue sections (eg, extra unstained slides), which
limit tissue wasting and improve turnaround time of final
results. Immunohistochemistry studies, if needed to diag-
nose metastatic CRC, should be limited in scope and stand-
ardized to preserve tissues.
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It is imperative to identify suspected metastatic CRC
specimens at specimen accessioning to limit unneeded ancil-
lary tests, such as liver biopsy special stains. Recognition of
previous CRC diagnoses from the patient clinical history
should limit the need for immunohistochemistry profiles in
many cases. Established laboratory procedures to identify
patients undergoing cancer biopsy or fine-needle aspiration
specifically for predictive molecular biomarker assessments
need to be in place.
Laboratories must maintain appropriate cataloguing
and storage of tissue specimens and diagnostic slides to
allow for retrospective timely testing of cancer samples.
This recommendation is supported by 15 studies,128-142
comprising eight prospective cohort studies130-133,136-138,142
and seven retrospective cohort studies.128,129,134,135,139-141
For the eight prospective cohort studies,130-133,136-138,142
all reported balance between the treatment and assessment
groups, as all but one132 used a single cohort design allow-
ing for within-group comparisons. Only this single study,
reported by Tol et al,132 would have required making
adjustments for imbalances between the treatment and
assessment groups, but none were needed. Five
studies130,133,136-138 reported nonindustry funding, one132
reported at least partial industry funding, one142 reported
industry funding, and one131 did not disclose the source of
funding, if any. Seven130,131,133,136-138,142 were deemed to
have a low risk of bias, and one132 was deemed to have a
low to moderate risk of bias.
For the seven retrospective cohort
studies,128,129,134,135,139-141 all used a single cohort design
allowing for within-group comparisons. Four reported
nonindustry funding,134,135,139,140 one reported industry
funding,129 and two did not disclose the source of fund-
ing, if any.128,141 Six were deemed to have a low risk of
bias,128,134,135,139-141 and one was deemed to have a mod-
erate risk of bias.129
All of the evidence that supported this recommendation
was assessed, and none had methodologic flaws that would
raise concerns about their findings.
15. Expert Consensus Opinion: Members of the
patient’s medical team, including pathologists, may initiate
colorectal carcinoma molecular biomarker test orders in
accordance with institutionally accepted practices.
For patients with CRC, timely diagnosis or therapeutic
initiation is critical, and molecular testing that is to be con-
sidered should be ordered as efficiently as possible in
accordance with institutional practices and guidelines. MSI
testing is often ordered at the time of diagnosis to identify
patients with Lynch syndrome, direct adjuvant chemother-
apy, or determine prognosis. Many institutions employ
algorithms to ensure that all colorectal cancers are evaluated
for MMR deficiency, and these are often initiated by pathol-
ogists when the diagnosis occurs after joint general process
approval by pathologists, oncologists, and other members of
the patient medical team. Molecular testing that is per-
formed to direct targeted therapy (eg, RAS) may be ordered
at a later date than the primary diagnosis, at metastatic pre-
sentation, for example, and so institutions may differ as to
whether one should order such testing upfront on the pri-
mary diagnostic biopsy or resection specimen or wait until
metastatic disease arises requiring targeted therapy. Often
oncologists order predictive molecular assays since they are
used to direct therapy, but this should not necessarily be lim-
ited to oncologists, as pathologists serve as important stew-
ards of the tissue and make the tumor diagnosis. There are
also issues to consider, including logistical issues, cost-
effectiveness, patient access to molecular testing in rural or
underserved areas, and even heterogeneity considerations
between primary and metastatic tumor. Since each institu-
tion differs in patient population, facilities, departmental
organization, regulatory and reimbursement climates, and
practitioner preference, whether to submit testing at initial
diagnosis of a primary lesion or when a metastatic lesion
arises should be discussed collaboratively between oncolo-
gists, pathologists, and medical executive or hospital com-
mittees as applicable.
“Reflex” testing, a testing policy that does not require a
separate clinician order for each case, is appropriate if
agreed upon by the CRC care team as an institutionally
approved standing order and may help to ensure expedited
and consistent routing of specimens for molecular testing.
However, some patients may not be candidates for targeted
therapy for clinical reasons, and good communication
between the clinical care team and the testing laboratory is
needed to ensure testing is performed for patients whose
management will be affected by the test result. Specifically,
testing is not necessary for patients with stage IV disease
who are being considered for palliative or hospice care only.
Similarly, in settings in which reflex testing is the practice,
a mechanism should be provided for the clinical care team
to communicate to the pathologist examining a small biopsy
or cytology sample when a more suitable diagnostic speci-
men (eg, a resection) is expected to be obtained, and the
molecular testing should be deferred to the subsequent,
more generous sample. All reflex testing should be
approved institutionally by the hospital or institution’s med-
ical executive committee as local policies dictate.
16. Expert Consensus Opinion: Laboratories that
require send out of tests for treatment predictive
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biomarkers should process and send colorectal carcinoma
specimens to reference molecular laboratories in a
timely manner.
Note: It is suggested that a benchmark of 90% of speci-
mens should be sent out within 3 working days.
It is critical to provide the results of molecular tests in
a timely fashion to start the most appropriate cancer treat-
ment option for each patient. Delays in initiation of ther-
apy have been associated with worse outcomes.127 To
date, laboratories have had limited guidance on the recom-
mended timing or turnaround time of molecular test
results, and studies addressing the impact of specific turn-
around times have not been conducted. Therefore, the
panel reached an expert consensus opinion, based on each
panel member’s practical experience in the laboratory and
clinical setting.
For laboratories that do not perform molecular testing
and/or biomarker immunohistochemistry for CRC therapy
selection, the consensus opinion was that send out of speci-
mens should occur within 3 working days, starting from the
day the test order was received in the laboratory, provided
the specimens (eg, biopsy or resection specimens) are
received at the same time of the test order or specimens are
already in the laboratory (eg, archived paraffin blocks). The
underlying rationale stems from the usual workflow for tis-
sue processing. In practice, the longest process would be the
processing of large surgical specimens, such as colectomies.
A possible approach is to obtain a designated molecular tis-
sue block at the time of specimen grossing, and molecular
protocols for obtaining tissue sections may be used to have
the necessary sections for test send-out in a timely fashion
by the third working day for most cases. Another scenario
may be the retrieval of archived tissue paraffin blocks that
may be stored outside of the laboratory location. In this
case, a protocol for block retrieval for molecular testing
may be operationalized to streamline the process and reach
the desired turnaround time for send-out. This turnaround
time of 3 working days was also recommended for RAS test-
ing of colorectal carcinoma in the guidance document from
the Association of Clinical Pathologists Molecular
Pathology and Diagnostics Group in the United
Kingdom.126
Laboratories should develop written policies as part of
their quality assurance program to monitor turnaround times
for all cancer therapeutic and prognostic biomarkers.
17. Expert Consensus Opinion: Pathologists must
evaluate candidate specimens for biomarker testing to
ensure specimen adequacy, taking into account tissue qual-
ity, quantity, and malignant tumor cell fraction. Specimen
adequacy findings should be documented in the patient
report.
It is critical that pathologists selecting blocks for bio-
marker testing understand the specimen requirements of the
method being employed in terms of total tissue amount (a
reflection of the total amount of DNA required for the
assays) and the fraction of malignant tumor cells in the
specimen focus to be evaluated. The total amount of tissue
selected for evaluation is significant in two respects. First,
the amount of tissue sampled should be of sufficient quan-
tity to produce a result that is reliably representative of the
entire tumor. While recent evidence indicates that some
genes continue to evolve during tumor progression, leading
to substantial tumor genetic heterogeneity, those driver
mutations of importance to CRC are usually, but not always,
homogeneous throughout the tumor. The amount of tumor
necessary, however, for a particular analytical method can
vary and demands knowledge and due attention to the indi-
cated tissue requirements for the specific assay employed.
The minimal required proportion of tumor DNA in a sam-
ple from cancer is dictated by the analytical sensitivity of
the particular validated assay. As shown in Table 13, the
amount of tumor used in the analyses of KRAS mutations
in several studies comparing the test-performing charac-
teristics of various assays varied widely, ranging from
1% to 90%.
The proportion of malignant tumor cells (as opposed to
tumor-associated nonmalignant cells, eg, stromal fibro-
blasts, endothelial cells, infiltrating inflammatory cells)
should be evaluated as accurately as possible and docu-
mented. This evaluation is most readily performed by esti-
mating the proportion of malignant cell nuclei to
nonmalignant cell nuclei within the focus selected for eval-
uation.143 Understanding that the number of mutated alleles
for a particular gene may represent as few as half of the
alleles in diploid tumor cells, a tumor cell focus with a nom-
inal proportion of 50% tumor cells would have a mutant
allele fraction of 25%, a value approaching the analytical
sensitivity of some molecular assays. So, while variety of
molecular methods can be used to evaluate tissue speci-
mens, it is critical that these be carefully matched to their
specific tissue and tumor cell proportion requirements.
When adhered to, all these of these methods can produce
accurate and reliable results.
Pathologists evaluating tissue section for biomarker
evaluation should also be aware that necrosis and tissue
degeneration can lead to erroneous results, and foci demon-
strating significant necrosis should be avoided for molecular
testing. Any amount of necrosis in the sample selected for
biomarker testing should be estimated and documented.
18. Expert Consensus Opinion: Laboratories should
use colorectal carcinoma molecular biomarker testing meth-
ods that are able to detect mutations in specimens with at
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least 5% mutant allele frequency, taking into account the
analytical sensitivity of the assay (limit of detection or
LOD) and tumor enrichment (eg, microdissection).
Note: It is recommended that the operational minimal
neoplastic carcinoma cell content tested should be set at
least two times the assay’s LOD.
Since the accuracy and results of testing for molecular
markers are dependent on both tumor cell content and the
assay-specific sensitivity in the identification of a mutant
allele against a background of wild-type/nonmutated alleles,
it is suggested that laboratories should establish minimum
acceptable tumor cell content as a component of their speci-
men requirements. It is recommended that a pathologist
reviews all cases for tumor cell content and quality. Due to
the stochastic nature of mutant allele identification at the
lower LOD, it is recommended that the minimal tumor cell
content be at least two times the lower LOD of a validated
molecular method or assay. This LOD was also recom-
mended for RAS testing of colorectal carcinoma in the guid-
ance document from the United Kingdom.126 Hence, if a
particular assay has a lower limit of mutant allele detection
of 5%, then the minimum tumor cell content in samples ana-
lyzed by this assay should be at least 10% to reliably detect
heterozygous mutations in those neoplasms. Due to intratu-
moral heterogeneity, subclones, and the nature of tissue
sampling, clinical trials have used 5% as the lower LOD,
and for clinical purposes, it is recommended that the lower
LOD for a mutant allele be at least 5%.12 Therefore, the uti-
lization of methods such as PCR, HRM, single-strand con-
formation polymorphism, pyrosequencing, or commercially
available kits that achieve this level of sensitivity is recom-
mended130,137,138,142 (Table 13).
This recommendation is supported by four prospective
cohort studies130,137,138,142 and two retrospective cohort
studies.102,144 The four prospective cohort studies all studied
a single cohort, allowing for within-group comparisons. For
this reason, all were balanced between comparison groups,
and no adjustments were needed to account for baseline dif-
ferences. All four reported nonindustry funding, and all
were deemed to have a low risk of bias.
The two retrospective cohort studies102,144 also used
single cohorts, allowing for within-group comparisons only.
One102 did not report the source of funding, while the
other144 reported nonindustry funding. Both were deemed to
have a low risk of bias.
None of the studies had methodologic flaws that would
raise concerns about their findings.
19. Expert Consensus Opinion: Colorectal carcinoma
molecular biomarker results should be made available as
promptly as feasible to inform therapeutic decision making,
both prognostic and predictive.
Note: It is suggested that a benchmark of 90% of
reports be available within 10 working days from date of
receipt in the molecular diagnostics laboratory.
Combined chemotherapy, including anti-EGFR ther-
apy, in patients with CRC in the absence of mutations in
the EGFR signaling pathway is associated with significant
survival advantage. No significant therapeutic benefit is
derived from anti-EGFR therapy in the presence of muta-
tions in KRAS and NRAS.44 The presence of deficient
MMR in stage II CRC indicates a good prognosis and iden-
tifies patients for whom adjuvant 5-fluorouracil mono-
based therapies have no significant benefit.145,146 The
presence of deficient MMR or BRAF p.V600E mutation in
proficient MMR CRCs has important prognostic
significance.54
In the absence of published data establishing an
evidence-based recommendation, it is our expert consensus
opinion that the above results, regardless of testing methods,
be available from test ordering in the initial diagnostic path-
ology laboratory to the clinical team within 2 weeks (10
working days). The 10 working days does not include the
time before the tissue specimen is available for testing (ie,
from diagnostic procedure to receipt in laboratory) or time
to retrieve tissue samples from an outside laboratory.
Laboratories unable to maintain this standard, either through
in-house testing or use of a reference laboratory, need to
implement measures to improve test result turnaround time.
A turnaround time of 7 working days was recommended for
RAS testing of colorectal carcinoma in the guidance docu-
ment from the Association of Clinical Pathologists
Molecular Pathology and Diagnostics Group in the United
Kingdom.126
This recommendation is supported by evidence from
one randomized controlled trial, reported by Douillard et
al.44 This report used prospective patient data collected
within the PRIME trial. While it did not report details on the
randomization, blinding, statistical power calculation, sam-
ple size, or length of follow-up, it did report on baseline
characteristics and was otherwise well reported. Funding
was reported to be partially from industry sources. Overall,
this trial was found to have a low to moderate risk of bias
and did not have methodologic flaws that would raise con-
cerns about its findings.
Each laboratory should develop a quality assurance pro-
gram to monitor turnaround times for all cancer therapeutic
and prognostic biomarkers.
20. Expert Consensus Opinion: Colorectal carcinoma
molecular biomarker testing reports should include a results
and interpretation section readily understandable by oncolo-
gists and pathologists. Appropriate Human Genome
Variation Society (HGVS) and HUGO nomenclature must
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be used in conjunction with any historical genetic
designations.
Reporting of molecular results is becoming more com-
plex as new information and clinical utility are discovered
for somatic variants. Single-gene assays are still being
widely used, but multiplexing has allowed for multiple pos-
sible results. With the introduction of NGS into the clinical
setting, multiple somatic mutations with clinical signifi-
cance may be identified. However, panel assays by NGS
can also reveal variants with unknown clinical significance.
As pathogenic genes and somatic mutations have been dis-
covered over the past 30 years, there has been divergent
nomenclature employed, making clinical reporting and clin-
ical analysis difficult. Presently and in the future, as national
databases are constructed annotating clinical somatic var-
iants, it is imperative that standardized nomenclature be
employed to identify the clinical significance of rare
variants.
Clinicians want a report that is easily readable and
understandable but that gives pertinent clinical information
concisely, accurately, and thoroughly. Reported variants
should be identified using both DNA and protein nomencla-
ture. Citing codon positivity only is not encouraged (eg,
positive for a KRAS codon 12 mutation); the specific muta-
tion should be explained using standardized nomenclature,
preferably HUGO gene nomenclature.112,147 Historical des-
ignations (eg, historical HER-2/neu, for HUGO ERBB2)
should also be included as appropriate in the report to avoid
confusion among oncologists. Importantly, the messenger
RNA transcript number (NM_#) from the NCBI, used to
designate the specific codon numbering, should be named in
the report since numbering can differ between the different/
alternative transcript designations for the same gene. If
using NGS, variants should at least be classified as patho-
genic, likely pathogenic, variant of unknown significance,
likely benign, or benign, but classification of somatic muta-
tions is still awaiting specifically approved guidelines.148
However, a numerical classification scheme for somatic
variants has been proposed, taking into consideration
actionability of the variant in the patient’s tumor type vs
other tumor types, predicted pathogenicity (using programs
such as SIFT and PolyPhen 2) in the patient’s tumor type vs
other tumor types, variant recurrence in a certain cancer
type, or unknown significance.149 Such a classification
scheme may be better suited to somatic variants considering
the indications for which most of these assays are being
ordered.
Reports should contain the analytical result, the method
used, and information about the genes and loci tested or
included in the assay; the assay limit of detection; and any
disclaimers (eg, ASR) that are required to meet regulations.
When reasonable and applicable, an interpretive comment
should be given to ensure that results are correctly under-
stood.112 Such an interpretive comment may include infor-
mation regarding therapeutic implications, prognostic
implications, and/or pathogenic significance of the mutation
and, when appropriate or desired, potential applicable clini-
cal trials.
In summary, molecular reports should be easily under-
standable by clinical oncologists and use standardized
nomenclature outlined by HGVS/HUGO. All reports should
contain the elements of result, interpretation, variant classi-
fication, and information as applicable; limit of detection of
the assay and methods to assist the oncologist in understand-
ing the test result; and limitations as they consider the result
in a clinical context.
21. Strong Recommendation: Laboratories must
incorporate colorectal carcinoma molecular biomarker test-
ing methods into their overall laboratory quality improve-
ment program, establishing appropriate quality
improvement monitors as needed to ensure consistent per-
formance in all steps of the testing and reporting process. In
particular, laboratories performing colorectal carcinoma
molecular biomarker testing must participate in formal pro-
ficiency testing programs, if available, or an alternative pro-
ficiency assurance activity.
Proficiency testing (PT) is an important component of
quality assurance for laboratory tests in general and applies
to the molecular tests discussed in the current CRC molecu-
lar testing guidelines. These include mutational as well as
immunohistochemical testing. Participation in PT allows
the assessment and comparison of test performance among
different clinical laboratories and technologies and allows
verification of accuracy and reliability of laboratory
tests.150
From a regulatory standpoint, PT in the United States
is a requirement for accreditation by the Centers for
Medicare & Medicaid Services. Participation in PT may
be done through CAP PT programs or through other pro-
viders accepted by CLIA.151 Other countries—namely,
the United Kingdom—follow similar guidelines, recom-
mending that laboratories providing RAS testing of CRC
should demonstrate successful participation in a relevant
external quality assurance scheme and be appropriately
accredited.126
Formal external proficiency testing programs for analy-
tes other than KRAS, MSI, MMR, and BRAF may not be
available at the time of this publication. Alternative profi-
ciency testing activities should be used. Appropriate alterna-
tive performance assessment procedures may include split
sample analysis with other laboratories or, if that is not
available, assessment of split samples with an established
in-house method and previously assayed material, which are
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run and interpreted by laboratory personnel who do not have
access to the prior results.151 If exchanging specimens with
other laboratories is the laboratory proficiency approach,
this should be done with one or more other laboratories at
least twice per year.105 Methods-based proficiency testing
(MBPT) refers to a testing approach that is based on
method, rather than based on each individual analyte tested.
MBPT is well established for several pathology subspecialty
areas, and the concept of MBPT complies with federal labo-
ratory regulations.151
Discussion on Emerging Biomarkers
Numerous studies have reported potential molecular
biomarkers for CRC prognosis, while fewer studies eval-
uated markers that could be predictive of response to spe-
cific treatments. Many published studies are limited due to
early exploratory and retrospective analyses, and those
biomarkers, while of potential interest, have not made it to
clinical practice. Our systematic review identified several
CRC molecular biomarkers that showed either prognostic
or treatment predictive characteristics in single studies
(Supplemental Table 15). Most of the molecular bio-
markers reported in the studies listed in the Supplemental
Table 15 were tested for expression by immunohistochem-
istry. Immunohistochemistry is notable for its widespread
availability in pathology laboratories but has limited quan-
titative capabilities due to difficult standardization of
quantitative or semiquantitative scoring, and is fraught by
significant interobserver variability. A problem of quanti-
tative assays, such as gene expression, microRNA expres-
sion, and methylation levels, tested in solid tumors, results
from the intrinsic mixed nature of the tissue with signifi-
cant variability of tumor and nontumor tissue content.
Another limitation of molecular biomarker discovery
approaches that rely on expression levels is that these bio-
markers have not been evaluated in the context of complex
molecular regulation of individual cancer subtypes. Their
fruitful use in the clinic may require further studies that
take into account computational predictions of biological
behavior and validation in prospective cohorts.
A great deal of interest has been raised recently for non-
invasive prognostic and/or therapy-predictive molecular bio-
markers, such as those tested in circulating tumor cells or
circulating nucleic acids, either as free nucleic acid in serum or
associated with extracellular vesicles or exosomes. This has
been referred to as “liquid biopsy.”152 Liquid biopsies may be
particularly useful in the management of patients with CRC to
identify recurrence, RAS mutation testing for emergence of
treatment resistance associated with anti-EGFR therapy, and
potential early cancer detection in defined subpopulations,
such as those at high risk of CRC. Overall, molecular
biomarkers for colorectal cancer tested in liquid biopsy sam-
ples are promising but await further validation.
Emerging data indicate that MMR status may have pre-
dictive value in some settings, specifically in patients with
advanced disease being considered for anti-PD-1/PD-L1
therapy.68,69
Conclusions
Evidence supports mutational testing of specific genes
in the EGFR signaling pathway, since they provide clini-
cally actionable information for targeted therapy of CRC
with anti-EGFR monoclonal antibodies. Mutations in some
of the biomarkers have clear prognostic value (BRAF,
MMR), and at least two (KRAS and NRAS) have relatively
strong evidence as negative predictors of benefit to anti-
EGFR therapies and should be used to guide the use of these
agents. BRAF mutations are consistently associated with
poor outcomes in patients with metastatic CRC, including
those who relapse after adjuvant therapy. Patients with
localized colon cancer and dMMR have improved out-
comes. Emerging data suggest that MMR status has predic-
tive value in some settings, specifically in patients with
advanced disease being considered for anti-PD-1/PD-L1
therapy.
Laboratory approaches to operationalize molecular test-
ing for predictive and prognostic molecular biomarkers
involve selection of assays, type of specimens to be tested,
timing of ordering of tests, and turnaround time for testing
results. A number of alternative technical approaches can
effectively be used as long as test specificity and sensitivity
meet the clinical needs. While earlier testing approaches
were focused on one or a few testing targets (eg, BRAF
p.V600 mutations), currently, new approaches are using
gene panels such as targeted NGS cancer panels, which can
range from a few to hundreds of genes and amplicons with
known mutational hotspots in cancer.
These guidelines will be subjected to regular updates,
such that new advances in the field can be captured and inte-
grated in the guidelines in a timely manner.
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Journal of Clinical Oncology. It has been edited in accordance
with standards established at the American Journal of Clinical
Pathology.
The authors gratefully acknowledge the following: expert
and advisory panel members Kevin Halling, MD, Charles
Blanke, MD, Pr. Jean-Franc¸ois Fle´jou, Heather Hampel, MS,
CGC, J. Randolph Hecht, MD, Kazunori Kanehira, MD, Faye
Kastrinos, MD, MPH, Carla B. MacLeod, MD, Peter J.
Odwyer, MD, Weijing Sun, MD, Josep Tabernero, MD, PhD,
Laura H. Tang, MD, PhD, Mary Kay Washington, MD, PhD,
Shuji Ogino, MD, PhD, MS, Loren Joseph, MD, Kim Ryan, and
Pamela McAllister, PhD, for their review of the key questions,
recommendations, and draft manuscript, as well as Kaitlin
Einhaus, Lisa A. Fatheree, SCT(ASCP), Jeff Jacobs, MA,
Sandra Larsen, MBA, MT(ASCP), Melvin Limson, PhD, John
Olsen, MD, Mrudula Pullambhatla, MS, Shiwen Song, MD,
Megan Wick, MT(ASCP), and Mary Steele Williams, MNA,
MT(ASCP)SM, CAE, for their support throughout the guideline
development process.
References
1. Febbo PG, Ladanyi M, Aldape KD, et al. NCCN task force
report: evaluating the clinical utility of tumor markers in
oncology. J Natl Compr Cancer Netw. 2011;9(suppl
5):S1-S33.
2. Grothey A. EGFR antibodies in colorectal cancer: where do
they belong? J Clin Oncol. 2010;28:4668-4670.
3. De Roock W, Claes B, Bernasconi D, et al. Effects of
KRAS, BRAF, NRAS, and PIK3CA mutations on the effi-
cacy of cetuximab plus chemotherapy in chemotherapy-
refractory metastatic colorectal cancer: a retrospective con-
sortium analysis. Lancet Oncol. 2010;11:753-762.
4. De Roock W, De Vriendt V, Normanno N, et al. KRAS,
BRAF, PIK3CA, and PTEN mutations: implications for tar-
geted therapies in metastatic colorectal cancer. Lancet
Oncol. 2011;12:594-603.
5. Rubenstein JH, Enns R, Heidelbaugh J, et al. American
Gastroenterological Association Institute guideline on the
diagnosis and management of Lynch syndrome.
Gastroenterology. 2015;149:777-782.
6. Des Guetz G, Schischmanoff O, Nicolas P, et al. Does
microsatellite instability predict the efficacy of adjuvant
chemotherapy in colorectal cancer? A systematic review
with meta-analysis. Eur J Cancer. 2009;45:1890-1896.
7. Guastadisegni C, Colafranceschi M, Ottini L, et al.
Microsatellite instability as a marker of prognosis and re-
sponse to therapy: a meta-analysis of colorectal cancer sur-
vival data. Eur J Cancer. 2010;46:2788-2798.
8. Gavin PG, Colangelo LH, Fumagalli D, et al. Mutation
profiling and microsatellite instability in stage II and III
colon cancer: an assessment of their prognostic and oxali-
platin predictive value. Clin Cancer Res.
2012;18:6531-6541.
9. Institute of Medicine. Clinical Practice Guidelines We
Can Trust. Washington, DC: National Academies
Press; 2011.
10. National Health and Medical Research Council. A guide to
the development, implementation and evaluation of clinicl
practice guidelines. 1999. https://www.nhmrc.gov.au/_files_
nhmrc/publications/attachments/cp.30.pdf. Accessed
March 23, 2016.
11. Guyatt GH, Oxman AD, Vist GE, et al; GRADE Working
Group. GRADE: an emerging consensus on rating quality
of evidence and strength of recommendations. BMJ.
2008;336:924-926.
12. Sorich MJ, Wiese MD, Rowland A, et al. Extended RAS
mutations and anti-EGFR monoclonal antibody survival
benefit in metastatic colorectal cancer: a meta-analysis of
randomized, controlled trials. Ann Oncol. 2015;26:13-21.
13. Ibrahim EM, Abouelkhair KM. Clinical outcome of panitu-
mumab for metastatic colorectal cancer with wild-type
KRAS status: a meta-analysis of randomized clinical trials.
Med Oncol. 2011;28(suppl 1):S310-S317.
14. Modest DP, Brodowicz T, Stintzing S, et al. Impact of the
specific mutation in KRAS codon 12 mutated tumors on
treatment efficacy in patients with metastatic colorectal
cancer receiving cetuximab-based first-line therapy: a
pooled analysis of three trials. Oncology. 2012;83:241-247.
15. Petrelli F, Borgonovo K, Cabiddu M, et al. Cetuximab and
panitumumab in KRAS wild-type colorectal cancer: a
meta-analysis. Int J Colorectal Dis. 2011;26:823-833.
16. Zhou SW, Huang YY, Wei Y, et al. No survival benefit from
adding cetuximab or panitumumab to oxaliplatin-based
chemotherapy in the first-line treatment of metastatic colo-
rectal cancer in KRAS wild type patients: a meta-analysis.
PLoS One. 2012;7:e50925.
17. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mu-
tations and benefit from cetuximab in advanced colorectal
cancer. N Engl J Med. 2008;359:1757-1765.
18. Adelstein BA, Dobbins TA, Harris CA, et al. A systematic
review and meta-analysis of KRAS status as the determin-
ant of response to anti-EGFR antibodies and the impact of
partner chemotherapy in metastatic colorectal cancer. Eur J
Cancer. 2011;47:1343-1354.
19. Allegra CJ, Jessup JM, Somerfield MR, et al. American
Society of Clinical Oncology provisional clinical
opinion: testing for KRAS gene mutations in patients
with metastatic colorectal carcinoma to predict re-
sponse to anti-epidermal growth factor receptor mono-
clonal antibody therapy. J Clin Oncol.
2009;27:2091-2096.
20. Baas JM, Krens LL, Guchelaar HJ, et al. Concordance of
predictive markers for EGFR inhibitors in primary tumors
and metastases in colorectal cancer: a review. Oncologist.
2011;16:1239-1249.
21. Chen J, Ye Y, Sun H, et al. Association between KRAS
codon 13 mutations and clinical response to anti-EGFR
treatment in patients with metastatic colorectal cancer: re-
sults from a meta-analysis. Cancer Chemother Pharmacol.
2013;71:265-272.
22. Dahabreh IJ, Terasawa T, Castaldi PJ, et al. Systematic
review: anti-epidermal growth factor receptor treatment
effect modification by KRAS mutations in advanced
colorectal cancer. Ann Intern Med. 2011;154:37-49.
23. De Roock W, Jonker DJ, Di Nicolantonio F, et al.
Association of KRAS p.G13D mutation with outcome in
patients with chemotherapy-refractory metastatic colorec-
tal cancer treated with cetuximab. JAMA.
2010;304:1812-1820.
24. Health Quality Ontario. KRAS testing for Anti-EGFR
therapy in advanced colorectal cancer: an evidence-based
and economic analysis. Ont Health Technol Assess Ser.
2010;10:1-49.
Sepulveda et al / ASCP/CAP/AMP/ASCO CRC BIOMARKER GUIDELINE
254 Am J Clin Pathol 2017;147:221-260 © American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology,
American Society of Clinical Oncology, and American Society for Investigative Pathology
254
DOI: 10.1093/ajcp/aqw209
D
ow
nloaded from
 https://academ
ic.oup.com
/ajcp/article-abstract/147/3/221/2967889 by U
niv of N
orth C
arolina at C
hapel H
ill H
ealth Sci Lib user on 12 August 2019
25. Hoyle M, Crathorne L, Peters J, et al. The clinical effective-
ness and cost-effectiveness of cetuximab (mono- or combin-
ation chemotherapy), bevacizumab (combination with
non-oxaliplatin chemotherapy) and panitumumab (mono-
therapy) for the treatment of metastatic colorectal cancer
after first-line chemotherapy (review of technology ap-
praisal No.150 and part review of technology appraisal No.
118): a systematic review and economic model. Health
Technol Assess. 2013;17:1-237.
26. Ibrahim EM, Zekri JM, Bin Sadiq BM. Cetuximab-based
therapy for metastatic colorectal cancer: a meta-analysis of
the effect of K-ras mutations. Int J Colorectal Dis.
2010;25:713-721.
27. Jiang Z, Li C, Li F, et al. EGFR gene copy number as a prog-
nostic marker in colorectal cancer patients treated with
cetuximab or panitumumab: a systematic review and meta
analysis. PLoS One. 2013;8:e56205.
28. Ku GY, Haaland BA, de Lima Lopes G Jr. Cetuximab in
the first-line treatment of K-ras wild-type metastatic
colorectal cancer: the choice and schedule of fluoropyri-
midine matters. Cancer Chemother Pharmacol. 2012;70:
231-238.
29. Lin AY, Buckley NS, Lu AT, et al. Effect of KRAS
mutational status in advanced colorectal cancer on the
outcomes of anti-epidermal growth factor receptor mono-
clonal antibody therapy: a systematic review
and meta-analysis. Clin Colorectal Cancer. 2011;10:63-69.
30. Linardou H, Dahabreh IJ, Kanaloupiti D, et al. Assessment
of somatic k-RAS mutations as a mechanism associated
with resistance to EGFR-targeted agents: a systematic re-
view and meta-analysis of studies in advanced non-small-
cell lung cancer and metastatic colorectal cancer. Lancet
Oncol. 2008;9:962-972.
31. Loupakis F, Cremolini C, Salvatore L, et al. Clinical impact
of anti-epidermal growth factor receptor monoclonal anti-
bodies in first-line treatment of metastatic colorectal can-
cer: meta-analytical estimation and implications for
therapeutic strategies. Cancer. 2012;118:1523-1532.
32. Mao C, Huang YF, Yang ZY, et al. KRAS p.G13D mutation
and codon 12 mutations are not created equal in predicting
clinical outcomes of cetuximab in metastatic colorectal
cancer: a systematic review and meta-analysis. Cancer.
2013;119:714-721.
33. Mao C, Yang ZY, Hu XF, et al. PIK3CA exon 20 mutations
as a potential biomarker for resistance to anti-EGFR mono-
clonal antibodies in KRAS wild-type metastatic colorectal
cancer: a systematic review and meta-analysis. Ann Oncol.
2012;23:1518-1525.
34. Petrelli F, Barni S. Resectability and outcome with anti-
EGFR agents in patients with KRAS wild-type colorectal
liver-limited metastases: a meta-analysis. Int J Colorectal
Dis. 2012;27:997-1004.
35. Petrelli F, Coinu A, Cabiddu M, et al. KRAS as prognostic
biomarker in metastatic colorectal cancer patients treated
with bevacizumab: a pooled analysis of 12 published trials.
Med Oncol. 2013;30:650.
36. Qiu LX, Mao C, Zhang J, et al. Predictive and prognostic
value of KRAS mutations in metastatic colorectal cancer
patients treated with cetuximab: a meta-analysis of 22 stud-
ies. Eur J Cancer. 2010;46:2781-2787.
37. Ren J, Li G, Ge J, et al. Is K-ras gene mutation a prognostic
factor for colorectal cancer: a systematic review and meta-
analysis. Dis Colon Rectum. 2012;55:913-923.
38. Tsoukalas N, Tzovaras AA, Tolia M, et al. Meta-analysis of
the predictive value of KRAS mutations in treatment re-
sponse using cetuximab in colorectal cancer. J BUON.
2012;17:73-78.
39. Vale CL, Tierney JF, Fisher D, et al. Does anti-EGFR ther-
apy improve outcome in advanced colorectal cancer? A sys-
tematic review and meta-analysis. Cancer Treat Rev.
2012;38:618-625.
40. Yang ZY, Shen WX, Hu XF, et al. EGFR gene copy number
as a predictive biomarker for the treatment of metastatic
colorectal cancer with anti-EGFR monoclonal antibodies: a
meta-analysis. J Hematol Oncol. 2012;5:52.
41. Zhang L, Ma L, Zhou Q. Overall and KRAS-specific results
of combined cetuximab treatment and chemotherapy for
metastatic colorectal cancer: a meta-analysis. Int J
Colorectal Dis. 2011;26:1025-1033.
42. Ross JS. Clinical implementation of KRAS testing in
metastatic colorectal carcinoma: the pathologist’s
perspective. Arch Pathol Lab Med. 2012;136:1298-
1307.
43. Bando H, Yoshino T, Shinozaki E, et al. Simultaneous iden-
tification of 36 mutations in KRAS codons 61 and 146,
BRAF, NRAS, and PIK3CA in a single reaction by multi-
plex assay kit. BMC Cancer. 2013;13:405.
44. Douillard JY, Oliner KS, Siena S, et al. Panitumumab-
FOLFOX4 treatment and RAS mutations in colorectal can-
cer. N Engl J Med. 2013;369:1023-1034.
45. Etienne-Grimaldi MC, Mahamat A, Chazal M, et al.
Molecular patterns in deficient mismatch repair colorec-
tal tumours: results from a French prospective multicen-
tric biological and genetic study. Br J Cancer. 2014;110:
2728-2737.
46. Van Cutsem E, Lenz HJ, Kohne CH, et al. Fluorouracil, leu-
covorin, and irinotecan plus cetuximab treatment and RAS
mutations in colorectal cancer. J Clin Oncol.
2015;33:692-700.
47. Xu Q, Xu AT, Zhu MM, et al. Predictive and prognostic
roles of BRAF mutation in patients with metastatic colorec-
tal cancer treated with anti-epidermal growth factor recep-
tor monoclonal antibodies: a meta-analysis. J Dig Dis.
2013;14:409-416.
48. Yuan ZX, Wang XY, Qin QY, et al. The prognostic role of
BRAF mutation in metastatic colorectal cancer receiving
anti-EGFR monoclonal antibodies: a meta-analysis. PLoS
One. 2013;8:e65995.
49. Forbes SA, Bhamra G, Bamford S, et al. The catalogue of
somatic mutations in cancer (COSMIC). Curr Protoc Hum
Genet. 2008;chap 10:unit 10.11.
50. Lin JS, Webber EM, Senger CA, et al. Systematic review of
pharmacogenetic testing for predicting clinical benefit to
anti-EGFR therapy in metastatic colorectal cancer. Am J
Cancer Res. 2011;1:650-662.
51. Mao C, Liao RY, Qiu LX, et al. BRAF V600E mutation and
resistance to anti-EGFR monoclonal antibodies in patients
with metastatic colorectal cancer: a meta-analysis. Mol Biol
Rep. 2011;38:2219-2223.
52. Parsons MT, Buchanan DD, Thompson B, et al.
Correlation of tumour BRAF mutations and MLH1 methy-
lation with germline mismatch repair (MMR) gene muta-
tion status: a literature review assessing utility of tumour
features for MMR variant classification. J Med Genet.
2012;49:151-157.
AJCP / REVIEW ARTICLE
© American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology,
American Society of Clinical Oncology, and American Society for Investigative Pathology
Am J Clin Pathol 2017;147:221-260 255
DOI: 10.1093/ajcp/aqw209
255
D
ow
nloaded from
 https://academ
ic.oup.com
/ajcp/article-abstract/147/3/221/2967889 by U
niv of N
orth C
arolina at C
hapel H
ill H
ealth Sci Lib user on 12 August 2019
53. Cui D, Cao D, Yang Y, et al. Effect of BRAF V600E muta-
tion on tumor response of anti-EGFR monoclonal antibod-
ies for first-line metastatic colorectal cancer treatment: a
meta-analysis of randomized studies. Mol Biol Rep.
2014;41:1291-1298.
54. Lochhead P, Kuchiba A, Imamura Y, et al. Microsatellite
instability and BRAF mutation testing in colorectal can-
cer prognostication. J Natl Cancer Inst. 2013;105:
1151-1156.
55. Rowland A, Dias MM, Wiese MD, et al. Meta-analysis of
BRAF mutation as a predictive biomarker of benefit from
anti-EGFR monoclonal antibody therapy for RAS wild-
type metastatic colorectal cancer. Br J Cancer.
2015;112:1888-1894.
56. Cremolini C, Loupakis F, Antoniotti C, et al. FOLFOXIRI
plus bevacizumab versus FOLFIRI plus bevacizumab as first-
line treatment of patients with metastatic colorectal cancer:
updated overall survival and molecular subgroup analyses of
the open-label, phase 3 TRIBE study. Lancet Oncol.
2015;16:1306-1315.
57. Corcoran RB, Atreya CE, Falchook GS, et al. Phase 1-2
trial of the BRAF inhibitor dabrafenib (D) plus MEK in-
hibitor trametinib (T) in BRAF V600 mutant colorectal
cancer (CRC): updated efficacy and biomarker analysis
[ASCO meeting abstract 3517]. J Clin Oncol.
2014;32:5s. http://meetinglibrary.asco.org/content/
131743-144. Accessed November 18, 2016.
58. Bendell JC, Atreya CE, Andre´ T, et al. Efficacy and toler-
ability in an open-label phase I/II study of MEK inhibitor
trametinib (T) BRAF inhibitor dabrafenib (D), and anti-
EGFR antibody panitumumab (P) in combination in pa-
tients (pts) with BRAF V600E mutated colorectal cancer
(CRC) [ASCO meeting abstract 3515]. J Clin Oncol.
2014;32:5s. http://meetinglibrary.asco.org/content/
131642-144. Accessed November 18, 2016.
59. Temraz S, Mukherji D, Shamseddine A. Dual inhibition
of MEK and PI3K pathway in KRAS and BRAF
mutated colorectal cancers. Int J Mol Sci.
2015;16:22976-22988.
60. Taieb J, Zaanan A, Le Malicot K, et al. Prognostic effect of
BRAF and KRAS mutations in patients with stage III colon
cancer treated with leucovorin, fluorouracil, and oxaliplatin
with or without cetuximab: a post hoc analysis of the
PETACC-8 trial [published online January 14, 2016].
JAMAOncol.
61. Barras D. BRAF mutation in colorectal cancer: an update.
Biomark Cancer. 2015;7:9-12.
62. Geiersbach KB, Samowitz WS. Microsatellite instability
and colorectal cancer. Arch Pathol Lab Med.
2011;135:1269-1277.
63. Barrow E, Hill J, Evans DG. Cancer risk in lynch syndrome.
Fam Cancer. 2013;12:229-240.
64. Schmeler KM, Lynch HT, Chen LM, et al. Prophylactic
surgery to reduce the risk of gynecologic cancers in the
Lynch syndrome. N Engl J Med. 2006;354:261-269.
65. Vasen HF, Blanco I, Aktan-Collan K, et al. Revised guide-
lines for the clinical management of Lynch syndrome
(HNPCC): recommendations by a group of European ex-
perts. Gut. 2013;62:812-823.
66. Funkhouser WK Jr, Lubin IM, Monzon FA, et al.
Relevance, pathogenesis, and testing algorithm for mis-
match repair-defective colorectal carcinomas: a report of
the Association for Molecular Pathology. J Mol Diagn.
2012;14:91-103.
67. Kawakami H, Zaanan A, Sinicrope FA. Implications of mis-
match repair-deficient status on management of early stage
colorectal cancer. J Gastrointest Oncol. 2015;6:676-684.
68. Diaz LA Jr, Le DT. PD-1 blockade in tumors with
mismatch-repair deficiency. N Engl J Med. 2015;373:1979.
69. Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors
with mismatch-repair deficiency. N Engl J Med. 2015;372:
2509-2520.
70. Le DT, Uram JN, Wang H, et al. Programmed death-1
blockade in mismatch repair deficient colorectal cancer
[ASCO meeting abstract 103]. J Clin Oncol. 2016;34. http://
meetinglibrary.asco.org/content/167415-176. Accessed
November 18, 2016.
71. Yang ZY, Wu XY, Huang YF, et al. Promising biomarkers
for predicting the outcomes of patients with KRAS wild-
type metastatic colorectal cancer treated with anti-
epidermal growth factor receptor monoclonal antibodies: a
systematic review with meta-analysis. Int J Cancer.
2013;133:1914-1925.
72. Pietrantonio F, Petrelli F, Coinu A, et al. Predictive role of
BRAF mutations in patients with advanced colorectal can-
cer receiving cetuximab and panitumumab: a meta-analysis.
Eur J Cancer. 2015;51:587-594.
73. Wu S, Gan Y, Wang X, et al. PIK3CA mutation is associ-
ated with poor survival among patients with metastatic
colorectal cancer following anti-EGFR monoclonal anti-
body therapy: a meta-analysis. J Cancer Res Clin Oncol.
2013;139:891-900.
74. Karapetis CS, Jonker D, Daneshmand M, et al. PIK3CA,
BRAF, and PTEN status and benefit from cetuximab in the
treatment of advanced colorectal cancer—results from
NCIC CTG/AGITG CO.17. Clin Cancer Res.
2014;20:744-753.
75. Liao X, Morikawa T, Lochhead P, et al. Prognostic role
of PIK3CA mutation in colorectal cancer: cohort study
and literature review. Clin Cancer Res.
2012;18:2257-2268.
76. Ogino S, Liao X, Imamura Y, et al. Predictive and prog-
nostic analysis of PIK3CA mutation in stage III colon
cancer intergroup trial. J Natl Cancer Inst.
2013;105:1789-1798.
77. Ogino S, Nosho K, Kirkner GJ, et al. PIK3CA mutation is
associated with poor prognosis among patients with curatively
resected colon cancer. J Clin Oncol. 2009;27:1477-1484.
78. Flossmann E, Rothwell PM. Effect of aspirin on long-term
risk of colorectal cancer: consistent evidence from rando-
mised and observational studies. Lancet. 2007;369:1603-
1613.
79. Jacobs EJ, Thun MJ, Bain EB, et al. A large cohort study of
long-term daily use of adult-strength aspirin and cancer in-
cidence. J Natl Cancer Inst. 2007;99:608-615.
80. Chan AT, Giovannucci EL, Meyerhardt JA, et al. Aspirin
dose and duration of use and risk of colorectal cancer in
men. Gastroenterology. 2008;134:21-28.
Sepulveda et al / ASCP/CAP/AMP/ASCO CRC BIOMARKER GUIDELINE
256 Am J Clin Pathol 2017;147:221-260 © American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology,
American Society of Clinical Oncology, and American Society for Investigative Pathology
256
DOI: 10.1093/ajcp/aqw209
D
ow
nloaded from
 https://academ
ic.oup.com
/ajcp/article-abstract/147/3/221/2967889 by U
niv of N
orth C
arolina at C
hapel H
ill H
ealth Sci Lib user on 12 August 2019
81. Domingo E, Church DN, Sieber O, et al. Evaluation of
PIK3CA mutation as a predictor of benefit from nonsteroi-
dal anti-inflammatory drug therapy in colorectal cancer.
J Clin Oncol. 2013;31:4297-4305.
82. Liao X, Lochhead P, Nishihara R, et al. Aspirin use, tumor
PIK3CA mutation, and colorectal-cancer survival. N Engl J
Med. 2012;367:1596-1606.
83. Kothari N, Kim R, Jorissen RN, et al. Impact of regular as-
pirin use on overall and cancer-specific survival in patients
with colorectal cancer harboring a PIK3CA mutation. Acta
Oncol. 2015;54:487-492.
84. Berg M, Danielsen SA, Ahlquist T, et al. DNA sequence
profiles of the colorectal cancer critical gene set KRAS-
BRAF-PIK3CA-PTEN-TP53 related to age at disease onset.
PLoS One. 2010;5:e13978.
85. Shen Y, Yang J, Xu Z, et al. Phosphatase and tensin homo-
log expression related to cetuximab effects in colorectal
cancer patients: a meta-analysis. World J Gastroenterol.
2012;18:2712-2718.
86. Wang ZH, Gao QY, Fang JY. Loss of PTEN expression as a
predictor of resistance to anti-EGFR monoclonal therapy
in metastatic colorectal cancer: evidence from retrospect-
ive studies. Cancer Chemother Pharmacol.
2012;69:1647-1655.
87. Nassif NT, Lobo GP, Wu X, et al. PTEN mutations are
common in sporadic microsatellite stable colorectal cancer.
Oncogene. 2004;23:617-628.
88. Sawai H, Yasuda A, Ochi N, et al. Loss of PTEN ex-
pression is associated with colorectal cancer liver metas-
tasis and poor patient survival. BMC Gastroenterol.
2008;8:56.
89. Lin MS, Huang JX, Chen WC, et al. Expression of
PPARgamma and PTEN in human colorectal cancer: an
immunohistochemical study using tissue microarray meth-
odology. Oncol Lett. 2011;2:1219-1224.
90. Li XH, Zheng HC, Takahashi H, et al. PTEN expression
and mutation in colorectal carcinomas. Oncol Rep.
2009;22:757-764.
91. Colakoglu T, Yildirim S, Kayaselcuk F, et al.
Clinicopathological significance of PTEN loss and the
phosphoinositide 3-kinase/Akt pathway in sporadic colo-
rectal neoplasms: is PTEN loss predictor of local recurrence?
Am J Surg. 2008;195:719-725.
92. Eklof V, Wikberg ML, Edin S, et al. The prognostic role of
KRAS, BRAF, PIK3CA and PTEN in colorectal cancer. Br
J Cancer. 2013;108:2153-2163.
93. Price TJ, Hardingham JE, Lee CK, et al. Prognostic impact
and the relevance of PTEN copy number alterations in pa-
tients with advanced colorectal cancer (CRC) receiving
bevacizumab. Cancer Med. 2013;2:277-285.
94. Frattini M, Saletti P, Romagnani E, et al. PTEN loss of ex-
pression predicts cetuximab efficacy in metastatic colorectal
cancer patients. Br J Cancer. 2007;97:1139-1145.
95. Perrone F, Lampis A, Orsenigo M, et al. PI3KCA/PTEN de-
regulation contributes to impaired responses to cetuximab
in metastatic colorectal cancer patients. Ann Oncol.
2009;20:84-90.
96. Sartore-Bianchi A, Martini M, Molinari F, et al. PIK3CA
mutations in colorectal cancer are associated with clinical
resistance to EGFR-targeted monoclonal antibodies. Cancer
Res. 2009;69:1851-1857.
97. Negri FV, Bozzetti C, Lagrasta CA, et al. PTEN status in
advanced colorectal cancer treated with cetuximab. Br J
Cancer. 2010;102:162-164.
98. Laurent-Puig P, Cayre A, Manceau G, et al. Analysis of
PTEN, BRAF, and EGFR status in determining bene-
fit from cetuximab therapy in wild-type KRAS
metastatic colon cancer. J Clin Oncol.
2009;27:5924-5930.
99. Tol J, Dijkstra JR, Klomp M, et al. Markers for EGFR path-
way activation as predictor of outcome in metastatic colo-
rectal cancer patients treated with or without cetuximab.
Eur J Cancer. 2010;46:1997-2009.
100. Ulivi P, Capelli L, Valgiusti M, et al. Predictive role of mul-
tiple gene alterations in response to cetuximab in metastatic
colorectal cancer: a single center study. J Transl Med.
2012;10:87.
101. Cejas P, Lopez-Gomez M, Aguayo C, et al. Analysis of the
concordance in the EGFR pathway status between primary
tumors and related metastases of colorectal cancer patients:
implications for cancer therapy. Curr Cancer Drug Targets.
2012;12:124-131.
102. Vakiani E, Janakiraman M, Shen R, et al. Comparative gen-
omic analysis of primary versus metastatic colorectal carcin-
omas. J Clin Oncol. 2012;30:2956-2962.
103. Lee KH, Kim JS, Lee CS, et al. KRAS discordance between
primary and recurrent tumors after radical resection of colo-
rectal cancers. J Surg Oncol. 2015;111:1059-1064.
104. Aisner DL, Deshpande C, Baloch Z, et al. Evaluation of
EGFR mutation status in cytology specimens: an insti-
tutional experience. Diagn Cytopathol.
2013;41:316-323.
105. Lindeman NI, Cagle PT, Beasley MB, et al. Molecular test-
ing guideline for selection of lung cancer patients for EGFR
and ALK tyrosine kinase inhibitors: guideline from the
College of American Pathologists, International
Association for the Study of Lung Cancer, and Association
for Molecular Pathology. Arch Pathol Lab Med.
2013;137:828-860.
106. Bettegowda C, Sausen M, Leary RJ, et al. Detection of cir-
culating tumor DNA in early- and late-stage human malig-
nancies. Sci Transl Med. 2014;6:224ra224.
107. Clinical Laboratory Improvement Amendments of 1988. 42
CFR §493.1351-1495 (1992).
108. Sakai K, Tsurutani J, Yamanaka T, et al. Extended RAS
and BRAF mutation analysis using next-generation
sequencing. PLoS One. 2015;10:e0121891.
109. Salto-Tellez M, Gonzalez de Castro D. Next-generation
sequencing: a change of paradigm in molecular diagnostic
validation. J Pathol. 2014;234:5-10.
110. Cottrell CE, Al-Kateb H, Bredemeyer AJ, et al. Validation
of a next-generation sequencing assay for clinical molecular
oncology. J Mol Diagn. 2014;16:89-105.
111. Clinical laboratory improvement amendments of 1988. 42
CFR §493.1253 (2003).
112. College of American Pathologists. CAP laboratory ac-
creditation checklists. http://www.cap.org/apps/cap.portal.
Accessed November 18, 2016.
113. Clinical and Laboratory Standards Institute. Establishing
molecular testing in clinical laboratory environments,
approved guideline (MM19-A). Wayne, PA: Clinical
Laboratory Standards Institute; 2011.
AJCP / REVIEW ARTICLE
© American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology,
American Society of Clinical Oncology, and American Society for Investigative Pathology
Am J Clin Pathol 2017;147:221-260 257
DOI: 10.1093/ajcp/aqw209
257
D
ow
nloaded from
 https://academ
ic.oup.com
/ajcp/article-abstract/147/3/221/2967889 by U
niv of N
orth C
arolina at C
hapel H
ill H
ealth Sci Lib user on 12 August 2019
114. Halling KC, Schrijver I, Persons DL. Test verification and
validation for molecular diagnostic assays. Arch Pathol Lab
Med. 2012;136:11-13.
115. Clinical and Laboratory Standards Institute. Molecular
Diagnostic Methods for Solid Tumors (Nonhematological
Neoplasms) (MM23-ED 1). Wayne, PA: Clinical
Laboratory Standards Institute; 2015.
116. Ogino S, Gulley ML, den Dunnen JT, et al. Standard
mutation nomenclature in molecular diagnostics:
practical and educational challenges. J Mol Diagn. 2007;
9:1-6.
117. Fishel R, Lescoe MK, Rao MR, et al. The human
mutator gene homolog MSH2 and its association with
hereditary nonpolyposis colon cancer. Cell. 1993;75:
1027-1038.
118. Bronner CE, Baker SM, Morrison PT, et al. Mutation in the
DNA mismatch repair gene homologue hMLH1 is associ-
ated with hereditary non-polyposis colon cancer. Nature.
1994;368:258-261.
119. Liu B, Nicolaides NC, Markowitz S, et al. Mismatch repair
gene defects in sporadic colorectal cancers with microsatel-
lite instability. Nat Genet. 1995;9:48-55.
120. Gologan A, Sepulveda AR. Microsatellite instability and
DNA mismatch repair deficiency testing in hereditary and
sporadic gastrointestinal cancers. Clin Lab Med.
2005;25:179-196.
121. Fitzgibbons PL, Bradley LA, Fatheree LA, et al.
Principles of analytic validation of immunohistochemi-
cal assays: guideline from the College of American
Pathologists Pathology and Laboratory Quality
Center. Arch Pathol Lab Med. 2014;138:1432-
1443.
122. Sepulveda AR. The importance of microsatellite instability
in colonic neoplasms. Medscape. 2008:571610. www.med
scape.org/viewarticle/571610. Accessed November 18,
2016.
123. Hatch SB, Lightfoot HM Jr, Garwacki CP, et al.
Microsatellite instability testing in colorectal carcinoma:
choice of markers affects sensitivity of detection of mis-
match repair-deficient tumors. Clin Cancer Res.
2005;11:2180-2187.
124. Watson N, Grieu F, Morris M, et al. Heterogeneous staining
for mismatch repair proteins during population-based pre-
screening for hereditary nonpolyposis colorectal cancer.
J Mol Diagn. 2007;9:472-478.
125. Cicek MS, Lindor NM, Gallinger S, et al. Quality assess-
ment and correlation of microsatellite instability and
immunohistochemical markers among population- and
clinic-based colorectal tumors results from the Colon
Cancer Family Registry. J Mol Diagn. 2011;13:271-
281.
126. Wong NA, Gonzalez D, Salto-Tellez M, et al. RAS testing
of colorectal carcinoma-a guidance document from the
Association of Clinical Pathologists Molecular
Pathology and Diagnostics Group. J Clin Pathol.
2014;67:751-757.
127. Biagi JJ, Raphael MJ, Mackillop WJ, et al. Association be-
tween time to initiation of adjuvant chemotherapy and sur-
vival in colorectal cancer: a systematic review and meta-
analysis. JAMA. 2011;305:2335-2342.
128. Franklin WA, Haney J, Sugita M, et al. KRAS muta-
tion: comparison of testing methods and tissue sam-
pling techniques in colon cancer. J Mol Diagn.
2010;12:43-50.
129. Laosinchai-Wolf W, Ye F, Tran V, et al. Sensitive multi-
plex detection of KRAS codons 12 and 13 mutations in
paraffin-embedded tissue specimens. J Clin Pathol.
2011;64:30-36.
130. Ma ES, Wong CL, Law FB, et al. Detection of KRAS muta-
tions in colorectal cancer by high-resolution melting ana-
lysis. J Clin Pathol. 2009;62:886-891.
131. Pinto P, Rocha P, Veiga I, et al. Comparison of methodolo-
gies for KRAS mutation detection in metastatic colorectal
cancer. Cancer Genet. 2011;204:439-446.
132. Tol J, Dijkstra JR, Vink-Borger ME, et al. High sensitivity
of both sequencing and real-time PCR analysis of KRAS
mutations in colorectal cancer tissue. J Cell Mol Med.
2010;14:2122-2131.
133. Buxhofer-Ausch V, Ausch C, Zeillinger R, et al. Duplex
reverse-hybridization assay for the simultaneous detection
of KRAS/BRAF mutations in FFPE-extracted genomic
DNA from colorectal cancer specimens. Dis Markers.
2013;34:171-177.
134. Carotenuto P, Roma C, Rachiglio AM, et al. Detection of
KRAS mutations in colorectal carcinoma patients with an
integrated PCR/sequencing and real-time PCR approach.
Pharmacogenomics. 2010;11:1169-1179.
135. Cavallini A, Valentini AM, Lippolis C, et al. KRAS geno-
typing as biomarker in colorectal cancer: a comparison of
three commercial kits on histologic material. Anticancer
Res. 2010;30:5251-5256.
136. Chang YS, Yeh KT, Hsu NC, et al. Detection of N-, H-,
and KRAS codons 12, 13, and 61 mutations with universal
RAS primer multiplex PCR and N-, H-, and KRAS-specific
primer extension. Clin Biochem. 2010;43:296-301.
137. Chen YL, Chang YS, Chang JG, et al. Genotyping of K-ras
codons 12 and 13 mutations in colorectal cancer by capil-
lary electrophoresis. J Chromatogr A.
2009;1216:5147-5154.
138. Chow L, Lin PC, Chang JS, et al. Differences in the fre-
quencies of K-ras c12-13 genotypes by gender and patho-
logic phenotypes in colorectal tumors measured using the
allele discrimination method. Environ Mol Mutagen.
2012;53:22-31.
139. Kristensen LS, Daugaard IL, Christensen M, et al. Increased
sensitivity of KRAS mutation detection by high-resolution
melting analysis of COLD-PCR products. HumMutat.
2010;31:1366-1373.
140. Kristensen LS, Kjeldsen TE, Hager H, et al. Competitive
amplification of differentially melting amplicons
(CADMA) improves KRAS hotspot mutation testing in
colorectal cancer. BMC Cancer. 2012;12:548.
141. Lang AH, Drexel H, Geller-Rhomberg S, et al. Optimized
allele-specific real-time PCR assays for the detection of
common mutations in KRAS and BRAF. J Mol Diagn.
2011;13:23-28.
142. Sundstrom M, Edlund K, Lindell M, et al. KRAS analysis in
colorectal carcinoma: analytical aspects of pyrosequencing
and allele-specific PCR in clinical practice. BMC Cancer.
2010;10:660.
Sepulveda et al / ASCP/CAP/AMP/ASCO CRC BIOMARKER GUIDELINE
258 Am J Clin Pathol 2017;147:221-260 © American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology,
American Society of Clinical Oncology, and American Society for Investigative Pathology
258
DOI: 10.1093/ajcp/aqw209
D
ow
nloaded from
 https://academ
ic.oup.com
/ajcp/article-abstract/147/3/221/2967889 by U
niv of N
orth C
arolina at C
hapel H
ill H
ealth Sci Lib user on 12 August 2019
143. Viray H, Li K, Long TA, et al. A prospective, multi-
institutional diagnostic trial to determine pathologist accur-
acy in estimation of percentage of malignant cells. Arch
Pathol Lab Med. 2013;137:1545-1549.
144. Nardon E, Glavac D, Benhattar J, et al. A multicenter study
to validate the reproducibility of MSI testing with a panel
of 5 quasimonomorphic mononucleotide repeats. Diagn Mol
Pathol. 2010;19:236-242.
145. Ribic CM, Sargent DJ, Moore MJ, et al. Tumor
microsatellite-instability status as a predictor of benefit
from fluorouracil-based adjuvant chemotherapy for colon
cancer. N Engl J Med. 2003;349:247-257.
146. Jover R, Zapater P, Castells A, et al. The efficacy of adju-
vant chemotherapy with 5-fluorouracil in colorectal cancer
depends on the mismatch repair status. Eur J Cancer.
2009;45:365-373.
147. Human Genome Variation Society. Human Genome
Variation Society website. www.hgvs.org. Updated
September 25, 2016. Accessed November 18, 2016.
148. Richards S, Aziz N, Bale S, et al. Standards and guidelines
for the interpretation of sequence variants: a joint
consensus recommendation of the American College
of Medical Genetics and Genomics and the
Association for Molecular Pathology. Genet Med.
2015;17:405-424.
149. Sukhai MA, Craddock KJ, Thomas M, et al. A classification
system for clinical relevance of somatic variants identified
in molecular profiling of cancer. Genet Med.
2016;18:128-136.
150. Kalman LV, Lubin IM, Barker S, et al. Current landscape
and new paradigms of proficiency testing and external qual-
ity assessment for molecular genetics. Arch Pathol Lab Med.
2013;137:983-988.
151. Schrijver I, Aziz N, Jennings LJ, et al. Methods-based profi-
ciency testing in molecular genetic pathology. J Mol Diagn.
2014;16:283-287.
152. Diaz LA, Jr, Bardelli A. Liquid biopsies: genotyping
circulating tumor DNA. J Clin Oncol. 2014;32:579-586.
Appendix 1
Disclosed Interests and Activities, 2010–June 2016
Name Interest/Activity Type Entity
Federico A. Monzon, MD Employment, stock options/bonds InVitae, 2011-2015
Castle Biosciences, 2015-present
Antonia R. Sepulveda, MD, PhD Consultant American Gastroenterological Society on endoscopy
and tissue sampling, 2015
Veena M. Singh, MD Employment, stock options/bonds Biocept
Consultant bioTheranostics
Lab PMM
Appendix 2
Disclosed Positions of Interest, 2010–June 2016a
Name Interest
Carmen J. Allegra, MD Deputy Director and GI Committee Co-Chair, NRG Oncology, 2014-Present
Senior Vice-President, NSABP Foundation, 2014-Present
Editor-in-Chief, Journal of the National Cancer Institute, 2012-Present
Allison M. Cushman-Vokoun, MD, PhD CAP Molecular Diagnostic, Genomic and Precision Medicine Resource Guide, CAP Personalized
Health Care (PHC) Committee
Molecular Pathology Representative, ASCP Curriculum Committee
Genetics Representative, AMP Training and Education Committee
CAP PHC Committee
William K. Funkhouser, MD, PhD CAP Molecular Oncology Committee, 2012-2016
Association of Directors of Anatomic and Surgical Pathology
Wayne Grody, MD, PhD President, American College of Medical Genetics and Genomics, 2011-2013
Stanley R. Hamilton, MD Member, National Cancer Institute (NCI) Colon Task Force, 2015-present
Journal of Pathology, Archives of Pathology and Laboratory Medicine, 2015-present
NCI Program for Assessment of Clinical Cancer Tests Working Group, 2015-present
Member, FDA Immunology Devices Panel, 2015-present
Member, Actionable Genome Consortium, 2015-present
MolDX Advisory Panel Member, Palmetto Medicare Administrative Contractor, 2015-present
CAP Co-Chair of Colorectal Molecular Markers Expert Panel, Physician Quality Reporting
Committee and Economic Affairs Committee, member, 2015-present
Member, CAP Cancer Biomarker Reporting Committee, 2015-present
Institute of Medicine Committee on Policy Issues in the Clinical Development and Use of
Biomarkers for Molecularly Targeted Therapies, sponsor and testimony on January 29, 2015,
2015-present
(continued)
AJCP / REVIEW ARTICLE
© American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology,
American Society of Clinical Oncology, and American Society for Investigative Pathology
Am J Clin Pathol 2017;147:221-260 259
DOI: 10.1093/ajcp/aqw209
259
D
ow
nloaded from
 https://academ
ic.oup.com
/ajcp/article-abstract/147/3/221/2967889 by U
niv of N
orth C
arolina at C
hapel H
ill H
ealth Sci Lib user on 12 August 2019
Appendix 2 (cont)
Name Interest
Member, Medical Evidence Development Consortium, 2015-present
Member, Center for Medicare and Medicaid Services (CMS) Medicare Evidence Development
and Coverage Advisory Committee, 2015-present
Member, CMS Advisory Panel on Clinical Diagnostic Laboratory Tests, 2015-present
Stanley R. Hamilton, MD
Scott E. Kopetz, MD, PhD Translational Sciences Representative, NCI Colon Task Force, 2012-2016
NCI Colon Task Force, Genomics Subcommittee, 2012-2016
Southwest Oncology Group (SWOG), 2012-2016
Colon Cancer, National Surgical Adjuvant Breast and Bowel Project, the Radiation Therapy
Oncology Group, and the Gynecologic Oncology Group (NRG) Cooperative Group, 2013-2016
Gastrointestinal Steering Committee, NCI, 2014-2016
SWOG, Translational Sciences GI Subcommittee, 2014-2016
GI Program, National Institutes of Health Cancer Center Support Grant, 2015-2016
Christopher Lieu, MD SWOG, Translational Sciences GI Subcommittee, 2015-2016
Noralane M. Lindor, MD Genetic Subcommittee of the Cancer Prevention Committee, ASCO, 2012-2015
Federico A. Monzon, MD President, AMP, 2017
President-Elect, AMP, 2016
Chair, Council of MGP Directors, AMP, 2014
AMP Co-Chair, CAP-ASCP-AMP Guideline Development for Colorectal Cancer Molecular
Testing, 2011-2013
Chair, Solid Tumor Subdivision and Council Member, AMP, 2012
Technology Assessment Committee member, CAP, 2008-2012
AMP, Clinical Practice Committee. 2009-2010
Bruce D. Minsky, MD Chair of the Board, American Society for Radiation Oncology
GI Steering Committee, NCI
Jan A. Nowak, MD, PhD CAP Center Committee, Pathology and Laboratory Quality Center, 2009-2015
CAP Public Health Policy Committee (formerly Patient Safety and Performance Measures
Committee), 2007-2011
CAP CGPA Molecular Pathology Working Group, 2008-2012
Ad Hoc Committee on Laboratory Quality and Improvement for the 21st Century LQI-21
Laboratory Developed Test Working Group, 2008-2010
CAP Molecular Pathology (Molecular Oncology) Resource Committee, 2005-2011
Measures and Performance Assessment Working Group, CAP Economic Affairs Committee,
2012-2013
Council on Governmental and Professional Affairs, PHCWorking Group, 2012-2016, CAP PHC
Associate Editor for Clinical Pathology, Archives of Pathology and Laboratory Medicine, 2012-
current
Member, CAP Guideline Metrics Expert Panel, 2014-current
AMA CPT Editorial Panel Member (American Hospital Association), 2015–current
AMA CPT Molecular Pathology Advisory Group, 2015-current
AMP Professional Relations Committee, 200-2012
AMP Economic Affairs Committee, 2009–current (co-chair, 2013-2014)
AMA CPT Editorial Panel Molecular Pathology Coding Working Tier 1 and Tier 2 Working
Groups, 2009-2012
Past-President, AMP, 2010
AMP Nominating Committee (chair), 2010
Pathology Coding Caucus—AMP Representative, 2005-2008, 2013-2015
CMS Medicare Evidence Development and Advisory Committee appointee, 2012
Daniel J. Sargent, PhD Alliance for Clinical Trials in Oncology, 2011-present
AMA, American Medical Association; CGPA, Council on Government and Professional Affairs; CPT, Current Procedural Terminology; FDA, Food and Drug Administration;
GI, gastrointestinal; MGP, molecular genetic pathology; NSABP, National Surgical Adjuvant Breast and Bowel Project.
aExpert panel members and staff Joseph Willis, MD, Jennifer Clark, SCT, MB(ASCP)CM, Carol Colasacco, MLIS, R. Bryan Rumble, MSc, Robyn Temple-Smolkin, PhD, and
Christina Ventura, MT(ASCP), have no reported conflicts of interest to disclose. The information above reflects disclosures that were collected and reviewed by the College of
American Pathologists (CAP), the American Society for Clinical Pathology (ASCP), the American Society of Clinical Oncology (ASCO), and the Association for Molecular
Pathology (AMP). The disclosures that appear in the individual journals of the societies may vary based on journal-specific policies and procedures.
Sepulveda et al / ASCP/CAP/AMP/ASCO CRC BIOMARKER GUIDELINE
260 Am J Clin Pathol 2017;147:221-260 © American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology,
American Society of Clinical Oncology, and American Society for Investigative Pathology
260
DOI: 10.1093/ajcp/aqw209
D
ow
nloaded from
 https://academ
ic.oup.com
/ajcp/article-abstract/147/3/221/2967889 by U
niv of N
orth C
arolina at C
hapel H
ill H
ealth Sci Lib user on 12 August 2019
